CN114487426A - Combined marker for predicting liver cancer risk of male hepatitis B virus infected person and application thereof - Google Patents
Combined marker for predicting liver cancer risk of male hepatitis B virus infected person and application thereof Download PDFInfo
- Publication number
- CN114487426A CN114487426A CN202011154456.5A CN202011154456A CN114487426A CN 114487426 A CN114487426 A CN 114487426A CN 202011154456 A CN202011154456 A CN 202011154456A CN 114487426 A CN114487426 A CN 114487426A
- Authority
- CN
- China
- Prior art keywords
- score
- content
- equal
- less
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 300
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 298
- 239000003550 marker Substances 0.000 title claims abstract description 26
- 241000700721 Hepatitis B virus Species 0.000 title claims abstract description 16
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims abstract description 556
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 309
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 231
- 238000001514 detection method Methods 0.000 claims abstract description 61
- 108010094028 Prothrombin Proteins 0.000 claims abstract description 17
- 102100027378 Prothrombin Human genes 0.000 claims abstract description 17
- 230000002159 abnormal effect Effects 0.000 claims abstract description 17
- 229940039716 prothrombin Drugs 0.000 claims abstract description 17
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 claims abstract description 16
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 claims abstract description 16
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims abstract description 16
- 108010088751 Albumins Proteins 0.000 claims abstract description 8
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims abstract 3
- 102100027211 Albumin Human genes 0.000 claims abstract 2
- 206010016654 Fibrosis Diseases 0.000 claims description 169
- 230000007882 cirrhosis Effects 0.000 claims description 169
- 238000004458 analytical method Methods 0.000 claims description 9
- 238000011156 evaluation Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000013058 risk prediction model Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 abstract description 35
- 238000012544 monitoring process Methods 0.000 abstract description 13
- 238000003745 diagnosis Methods 0.000 abstract description 12
- 238000003384 imaging method Methods 0.000 abstract description 4
- 230000005180 public health Effects 0.000 abstract description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 553
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 58
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 49
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 238000012549 training Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 238000013517 stratification Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 210000000601 blood cell Anatomy 0.000 description 7
- 238000012502 risk assessment Methods 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 238000007477 logistic regression Methods 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- -1 DCP Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 108010063628 acarboxyprothrombin Proteins 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002091 elastography Methods 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000005980 lung dysfunction Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 238000009557 abdominal ultrasonography Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012106 screening analysis Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57476—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofetal proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
- G01N2333/765—Serum albumin, e.g. HSA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a combined marker for predicting liver cancer risk of a male hepatitis B virus infected person and application thereof, wherein the combined marker comprises at least one of gamma-glutamyl transpeptidase, platelets, leukocytes, albumin and liver cirrhosis indexes, alpha-fetoprotein and abnormal prothrombin. The invention can realize early warning in liver cancer high-risk patients 1-2 years before HCC nodules appear in imaging, improves the diagnosis and detection rate of very early liver cancer (<3cm), simultaneously relieves the worry of a plurality of low-risk asymptomatic HBsAg positive patients, and reduces the monitoring and screening frequency of HCC. 4) From a public health perspective, cost-effective hierarchical screening can be achieved.
Description
Technical Field
The invention belongs to the technical field of biological medical treatment, and relates to a combined marker for predicting liver cancer risk of a male hepatitis B virus infected person and application thereof.
Background
Hepatocellular Carcinoma (HCC) is the main pathological type of the primary liver cancer, and the early HCC patients can be discovered to be treated properly and the prognosis can be improved by monitoring HCC high risk groups regularly. Patients with liver cirrhosis are generally recognized as high risk group of HCC, and related professional academic institutions in the world recommend the regular monitoring of HCC for patients with liver cirrhosis, and the examination of serum alpha-fetoprotein (AFP) combined with abdominal B ultrasound is usually performed every 3-6 months. In countries with advanced economy and abundant medical and health resources, such as the american liver disease research association (AASLD), except for regular HCC monitoring of patients diagnosed with liver cirrhosis, all asians of chronic HBV infection of men over 40 years old and women over 50 years old are also included in target population of HCC monitoring. However, the asia-pacific association of liver diseases (APASL) including china only recommends regular monitoring of HCC in the cirrhosis population, and asymptomatic chronic HBsAg-positive persons are not included in HCC monitoring personnel, and thus many HCC at early stages cannot be found in time. Since China has high HBsAg positive rate and liver cancer death rate, all asymptomatic HBsAg positive persons of 35-69 years old are screened locally in a plurality of areas with high liver cancer incidence in 2007 by combining serum alpha fetoprotein and abdominal ultrasonography B once every 6 months (namely 2 times per year) continuously for early HCC (AFP/US). However, practical work has found that the following major problems exist: 1) HCC monitoring 2 times a year, causing great anxiety in many asymptomatic HBsAg-positive patients and increasing much follow-up effort; 2) HCC monitoring and screening are carried out on all HBsAg positive population, and the technical scheme has no effect of improving the long-term survival of the population; 3) HCC monitoring and screening is less cost effective in all HBsAg positive populations. At present, 9300 million HBsAg positive population exist in China, and all the populations cannot be monitored for HCC by adopting AFP/US 2 times per year. Therefore, how to find and determine the population really requiring HCC monitoring is a problem to be solved urgently by scientists and clinical workers and an urgent need of asymptomatic HBsAg positive patients.
In the past decades, many hospitals and research institutions in Asian regions have studied HCC risk models based on HBV replication status, such as REVEAL-nomogram, CUHK clinical screening system, GAG-HCC risk score, IPM, etc., with hepatitis patients receiving relevant treatment at the hospital as the subjects. However, the development course of HCC is changed by the wide application of the nucleoside analogue antiviral drugs at present, the parameters in the model are difficult to reflect the risk of HCC, and related researchers also research liver cancer risk models such as PAGE-B, mPAGE and SAGE-B, Toronto HCC risk index, THRI and the like. HCC incidence in men is 3 times higher than in women, and even higher in HBV infected people, up to 6 times different. These models are 1) for hepatitis patients; 2) transient elastography techniques are required; 3) long-term, i.e., 5 years and longer, HCC predictions are typically made. These models have the following problems: 1) the effect in asymptomatic HBsAg-positive populations is unknown; 2) significant gender differences exist in relevant clinical detection values in normal population, but unified standards and values are adopted in the model; 3) the instantaneous elastography technology requires special instruments, is expensive and is susceptible to subjective interpretation; 4) it is difficult to reflect the recent HCC occurrence within 1-2 years, thereby causing anxiety in high risk populations.
Disclosure of Invention
The invention aims to provide a combined marker for predicting liver cancer risk of a male HBV (hepatitis B virus) infected person, and further performing individualized analysis on liver cancer occurrence risk of an asymptomatic male HBV infected person within 1-2 years; in liver cancer high-risk patients, early warning can be realized 1-2 years before HCC nodules appear in imaging, and the diagnosis and detection rate of liver cancer (less than 3cm) in an extremely early stage are improved; eliminates the concern of many low-risk asymptomatic HBV infected persons, and reduces the frequency of HCC monitoring and screening. From the perspective of public health, economical and effective layered screening is realized.
The invention provides a marker combination for predicting liver cancer risk of a person to be evaluated, which comprises gamma-glutamyl transpeptidase, at least one of platelet, leucocyte, albumin and liver cirrhosis indexes, alpha-fetoprotein and abnormal prothrombin.
Further, the marker combination includes alpha-fetoprotein, abnormal prothrombin, gamma-glutamyl transpeptidase, platelets, and leukocytes.
The alpha fetoprotein in the marker is an alpha fetoprotein index and is realized by detecting substances of alpha fetoprotein content; the abnormal prothrombin in the marker is an abnormal prothrombin index and is realized by detecting a substance with abnormal prothrombin content; the gamma-glutamyl transpeptidase is a gamma-glutamyl transpeptidase index and is realized by detecting the content of gamma-glutamyl transpeptidase; the platelets in the marker are platelet counting indexes and are realized by detecting substances for counting the platelets; the white blood cells in the marker are white blood cell counting indexes and are realized by detecting substances for counting the white blood cells; the albumin in the marker is an albumin index and is realized by detecting substances of albumin content; the liver cirrhosis index is obtained through B ultrasonic detection, and specifically, whether the person to be evaluated has liver cirrhosis or not is diagnosed through B ultrasonic detection.
The person to be evaluated is a male with liver cirrhosis or without liver cirrhosis, which is diagnosed by B-ultrasonic detection.
The marker is applied to the preparation of a system for predicting the liver cancer risk of a male hepatitis B virus infected person.
In the above applications, the system may be a reagent, a kit and/or an apparatus.
In the above applications, the system may include alpha-fetoprotein, abnormal prothrombin, and gamma-glutamyl transpeptidase. The alpha-fetoprotein, the abnormal prothrombin and the gamma-glutamyl transpeptidase can be used as standards for quantitative detection (such as standards in a spectral, chromatographic or/and mass spectrum detection method or standards in an enzyme-linked immunosorbent assay detection method).
In the above applications, the system may include other reagents and/or instruments necessary for the detection of alpha-fetoprotein content, abnormal prothrombin content and gamma-glutamyl transpeptidase content by spectroscopic, chromatographic or/and mass spectrometric methods.
In the above applications, the system may include other reagents and/or instruments necessary for detecting alpha-fetoprotein content, abnormal prothrombin content by enzyme-linked immunosorbent assay.
In the above application, the system may further comprise a fully automatic blood cell counter and a reagent for measuring a platelet count and a white blood cell count in blood using the fully automatic blood cell counter.
The substance for detecting the content of the abnormal prothrombin comprises the abnormal prothrombin; the substance for detecting the content of alpha-fetoprotein comprises alpha-fetoprotein; the substance for detecting the content of gamma-glutamyl transpeptidase comprises gamma-glutamyl transpeptidase.
The substance for detecting the content of the abnormal prothrombin comprises a specific binding agent of the abnormal prothrombin; the substance for detecting the content of the alpha-fetoprotein comprises a specific conjugate of the alpha-fetoprotein; the substance for detecting the content of gamma-glutamyl transpeptidase comprises a specific conjugate of gamma-glutamyl transpeptidase.
The substance for detecting the platelet count comprises a full-automatic blood cell counter and a reagent for measuring the platelet count in blood by using the full-automatic blood cell counter; the material for detecting the white blood cell count comprises a full-automatic blood cell counter and a reagent for measuring the white blood cell count in blood by using the full-automatic blood cell counter.
The test object of the system is HBsAg positive male of 35-69 years old.
The invention also provides a system for predicting the liver cancer risk of the male hepatitis B virus infected person, which comprises a detection device, wherein the detection device is used for detecting the detection numerical value of each marker in the marker combination in the body of the person to be evaluated.
The system also comprises an analysis module which is used for calculating a liver cancer risk value or a liver cancer risk score according to the liver cancer risk model by using the detection data obtained by the detection device, and then grading the liver cancer risk of the person to be evaluated according to the liver cancer risk value or the liver cancer risk score. The analysis module may reside on a processor or computer of the system.
The liver cancer risk model is shown as formula I: the formula I is: liver cancer risk value (P) ═ ex/(1+ex)；
Wherein x is the sum of the intercept + the regression coefficient (beta) corresponding to the detection result of each marker in the corresponding value range.
Wherein x in the formula I is any one of the following, wherein AFP is an abbreviation of alpha fetoprotein; DCP is an abbreviation for abnormal prothrombin; GGT is an abbreviation for γ -glutamyl transpeptidase; PLT is an abbreviation for platelets; WBC is an abbreviation for white blood cells; ALB is an abbreviation for albumin:
A1) x is-7.221 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT) + beta (WBC); the corresponding liver cancer risk model is named as a liver cancer risk model M02;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; when the age is less than 60 years and is not less than 45, beta (age) is 0.765; when the age is more than or equal to 60 and less than 65 years, the beta (age) is 1.668; when the age is more than or equal to 65 years, beta (age) is 1.62;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the AFP content is more than or equal to 7 and less than 20ng/mL, and the beta (AFP) is 1.162; the content of AFP is more than or equal to 20 and less than 80ng/mL, and the content of beta (AFP) is 1.335; the AFP content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.003; the AFP content is more than or equal to 400ng/mL, and the beta (AFP) is 3.432;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.125; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.897; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.332; the content is more than or equal to 120mAU/mL, beta (DCP) is 5.458
Wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.348; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.923; the content is more than or equal to 80U/L, and the beta (GGT) is 1.381;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, and the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ] 0.423; counting<80*109/L，β(PLT)＝1.434
Wherein β (WBC) represents the corresponding regression coefficient of WBC count in the corresponding value range, WBC: count is not less than 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.612；
A2) x is-8.484 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT) + beta (WBC) + beta (ALB), and the corresponding liver cancer risk model is named as a liver cancer risk model M01;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.699; 60 is less than 65 years old, beta (age) is 1.665; age is more than or equal to 65 years, beta (age) is 1.595;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.217; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.471; the content of 80 is less than or equal to 400ng/mL, and beta (AFP) is 2.263; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.850;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.057; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.821; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.376; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.447;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.348; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.979; the content is more than or equal to 80U/L, and beta (GGT) is 1.463;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, and the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of/L ≤＜150*109L, [ beta ] (PLT) ] 0.426; counting<80*109/L，β(PLT)＝1.527；
Wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, and the WBC count is not less than 4 x 106L,. beta. (WBC) ═ 0; WBC count<4*106/L，β(WBC)＝0.651；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.325;
A3) x is-6.091 + beta (age) + beta (AFP) + beta (DCP) + beta (PLT), and the corresponding liver cancer risk model is named as a liver cancer risk model M04;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years, and the beta (age) is 0; age is not less than 45 and less than 60 years, beta (age) is 0.638; 60 is less than or equal to age 65, beta (age) is 1.594; age is more than or equal to 65 years, beta (age) is 1.424;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and beta (AFP) is 1.459; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.715; the content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.337; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.740;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 0.988; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.790; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.114; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.506;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, and the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ] 0.659; counting<80*109/L，β(PLT)＝1.887；
A4) X is-8.293 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (WBC) + beta (ALB), and the corresponding liver cancer risk model is named as a liver cancer risk model M06;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is not less than 45 and less than 60 years, beta (age) is 0.810; age 60 is less than 65 years, beta (age) is 1.798; age is more than or equal to 65 years, beta (age) is 1.608;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.382; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.632; the content of 80 is less than or equal to 400ng/mL, and beta (AFP) is 2.408; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.979;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.023; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.850; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.558; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.401;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content is more than or equal to 20 and less than 45U/L, and the beta (GGT) is 1.477; the content of 45 is less than or equal to 80U/L, and the beta (GGT) is 2.050; the content is more than or equal to 80U/L, and the beta (GGT) is 1.598;
wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is more than or equal to 4 x 106L, [ beta ] (WBC) ═ 0; counting<4*106/L，β(WBC)＝1.129；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB content is less than 38g/L, the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.216;
A5) x is-8.384 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT) + beta (ALB), and the corresponding liver cancer risk model is named as a liver cancer risk model M07;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.701; 60 is less than or equal to age 65, beta (age) is 1.672; the age is more than or equal to 65 years, and beta (age) is 1.603;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content is more than or equal to 7 and less than 20ng/mL, and the beta (AFP) is 1.221; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.498; the content of 80 is less than or equal to 400ng/mL, and beta (AFP) is 2.346; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.743;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.041; the content of 40 is less than or equal to 50mAU/mL, and beta (DCP) is 2.856; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.353; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.407;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and the beta (GGT) is 1.321; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.981; the content is more than or equal to 80U/L, and beta (GGT) is 1.433;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ═ 0.505; counting<80*109/L，β(PLT)＝1.805；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB: the content is <38g/L, beta (ALB) ═ 0; the content is more than or equal to 38g/L, and the beta (ALB) is 1.284;
A6) x is-7.115 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (WBC), and the corresponding liver cancer risk model is named as a liver cancer risk model M09;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; 45 is less than or equal to age of 60 years, beta (age) is 0.857; 60 is less than or equal to age 65, beta (age) is 1.781; the age is more than or equal to 65 years, and beta (age) is 1.616;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.323; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.492; the content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.165; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.579;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.079; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.917; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.499; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.428;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and the beta (GGT) is 1.466; the content of 45 is less than or equal to 80U/L, and the beta (GGT) is 2.000; the content is more than or equal to 80U/L, and beta (GGT) is 1.520;
wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is more than or equal to 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝1.061；
A7) X is-7.162 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT), and the corresponding liver cancer risk model is named as a liver cancer risk model M10;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.762; 60 is less than 65 years old, beta (age) is 1.678; the age is more than or equal to 65 years, and beta (age) is 1.633;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and beta (AFP) is 1.161; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.376; the content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.093; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.350;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.105; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.920; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.304; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.411;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.327; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.924; the content is more than or equal to 80U/L, and the beta (GGT) is 1.350;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109PLT count < 150 x 10/L9L, [ beta ] (PLT) ] 0.500; PLT counting<80*109/L，β(PLT)＝1.696；
A8) X is-8.988 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT) + beta (WBC) + beta (ALB) + beta (cirrhosis), and the corresponding liver cancer risk model is named as a liver cancer risk model CM 01;
regression coefficients (β) corresponding to the detection results of each marker in the corresponding value ranges:
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.734; 60 is less than or equal to age 65, beta (age) is 1.734; the age is more than or equal to 65 years, and beta (age) is 1.640;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.090; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.302; the content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.011; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.875;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.170; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.982; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.313; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.277;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.049; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.576; the content is more than or equal to 80U/L, and beta (GGT) is 1.371;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ] 0.020; counting<80*109/L，β(PLT)＝0.766；
Wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is more than or equal to 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.333；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB content is less than 38g/L, the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.431;
wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: is, β (cirrhosis) ═ 2.108; no, β (cirrhosis) is 0;
A9) x is-7.627 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT) + beta (WBC) + beta (cirrhosis), and the corresponding liver cancer risk model is named as a liver cancer risk model CM 02;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.806; 60 is less than or equal to age 65, beta (age) is 1.699; age is more than or equal to 65 years, beta (age) is 1.701;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and beta (AFP) is 1.063; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.179; the content of 80 is less than or equal to 400ng/mL, and the beta (AFP) is 1.732; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.614;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.242; the content of 40 is less than or equal to 50mAU/mL, and the beta (DCP) is 3.086; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.305; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.277;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.057; the content of 45 is less than or equal to 80U/L, and the beta (GGT) is 1.528; the content is more than or equal to 80U/L, and beta (GGT) is 1.258;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ] 0.027; counting<80*109/L，β(PLT)＝0.647；
Wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is more than or equal to 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.301；
Wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: β (cirrhosis) ═ 2.084; no, β (cirrhosis) is 0;
A10) x is-4.541 + beta (age) + beta (AFP) + beta (DCP) + beta (PLT) + beta (cirrhosis), and the corresponding liver cancer risk model is named as a liver cancer risk model CM 04;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.738; 60 is less than or equal to age 65, beta (age) is 1.676; the age is more than or equal to 65 years, and beta (age) is 1.550;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.362; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.466; the content of 80 is less than or equal to 400ng/mL, and the beta (AFP) is 1.937; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.912;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.143; the content of 40 is less than or equal to 50mAU/mL, and beta (DCP) is 3.000; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.188; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.301;
wherein, beta (PLT) represents that the PLT count corresponds to the PLT count in the corresponding value rangeWhen the PLT count is not less than 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ═ 0.160; counting<80*109/L，β(PLT)＝0.813；
Wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: is, β (cirrhosis) ═ 2.286; no, β (cirrhosis) is 0;
A11) x is-6.681 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (WBC) + beta (ALB) + beta (liver cirrhosis), and the corresponding liver cancer risk model is named as a liver cancer risk model CM 06;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.781; 60 is less than or equal to age 65 years, beta (age) is 1.800; the age is more than or equal to 65 years, and beta (age) is 1.635;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.133; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.282; the content of 80 is less than or equal to 400ng/mL, and the beta (AFP) is 2.014; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.841;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.166; the content of 40 is less than or equal to 50mAU/mL, and beta (DCP) is 3.015; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.362; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.219;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and the beta (GGT) is 1.065; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.540; the content is more than or equal to 80U/L, and the beta (GGT) is 1.378;
wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is not less than 4 × 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.600；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB content is less than 38g/L, the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.328;
wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: β (cirrhosis) ═ 2.215; no, β (cirrhosis) is 0;
A12) x is-6.825 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT) + beta (ALB) + beta (cirrhosis), and the corresponding liver cancer risk model is named as a liver cancer risk model CM 07;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; 45 is less than or equal to age of 60 years, beta (age) is 0.755; 60 is less than or equal to age 65, beta (age) is 1.752; age is greater than or equal to 65 years, beta (age) is 1.651
Wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.093; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.325; the content of 80 is less than or equal to 400ng/mL, and the beta (AFP) is 2.034; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.844;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.157; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.995; the content of 50 is less than or equal to 120mAU/mL, and the beta (DCP) is 4.295; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.248;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content is more than or equal to 20 and less than 45U/L, and beta (GGT) is 1.035; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.573; the content is more than or equal to 80U/L, and the beta (GGT) is 1.343;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109L is not more than count < 150 x 109L,. beta. (PLT) ═ 0.056; counting<80*109/L，β(PLT)＝0.913；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB content is less than 38g/L, the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.411;
wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: β (cirrhosis) ═ 2.136; no, β (cirrhosis) is 0;
A13) x is-5.445 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (WBC) + beta (cirrhosis), and the corresponding liver cancer risk model is named as a liver cancer risk model CM 09;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; 45 is less than 60 years old, beta (age) is 0.836; age 60 is less than 65 years, beta (age) is 1.749; the age is more than or equal to 65 years, and beta (age) is 1.689;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.098; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.173; the content of 80 is less than or equal to 400ng/mL, and beta (AFP) is 1.751; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.607;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, when the DCP: content <20mAU/mL, β (DCP) ═ 0; the content is more than or equal to 20 and less than 40mAU/mL, and the beta (DCP) is 1.232; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 3.114; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.439; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.237;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT: the content is less than 20U/L, and beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.076; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.509; the content is more than or equal to 80U/L, and the beta (GGT) is 1.275;
wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is more than or equal to 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.529；
Wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: is, β (cirrhosis) ═ 2.183; no, β (cirrhosis) is 0;
A14) x is-5.506 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT) + beta (cirrhosis), and the corresponding liver cancer risk model is named as a liver cancer risk model CM 10;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; 45 is less than or equal to age of 60 years, beta (age) is 0.822; 60 is less than or equal to age 65, beta (age) is 1.715; the age is more than or equal to 65 years, and beta (age) is 1.712;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content is more than or equal to 7 and less than 20ng/mL, and the beta (AFP) is 1.062; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.202; the content of 80 is less than or equal to 400ng/mL, and beta (AFP) is 1.765; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.596;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.227; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 3.095; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.286; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.246;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.046; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.527; the content is more than or equal to 80U/L, and beta (GGT) is 1.231;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L,. beta. (PLT) ═ 0.059; counting<80*109/L，β(PLT)＝0.780；
Wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: is, β (cirrhosis) ═ 2.109; otherwise, β (cirrhosis) is 0.
Further, the liver cancer risk model may be: the liver cancer risk score is the sum of the corresponding scores of the detection results of all markers in the corresponding value ranges; the combination of markers is any one of the following:
B1) the liver cancer risk score is age score, AFP score, DCP score, GGT score, PLT score and WBC score, the model is named as a liver cancer risk score model M02,
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.8; the age is more than or equal to 60 and less than 65 years, and the age score is 3.9; the age is more than or equal to 65 years, and the age score is 3.8 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.7 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 3.2 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 4.7 points; the content is more than or equal to 400ng/mL, and the AFP score is 8.1 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 2.7 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 6.8 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 10.2 points; the content is more than or equal to 120mAU/mL, and the DCP score is 12.9 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 3.2 points; the content of 45 is less than 80U/L, and the GGT score is 4.5 points; the content is more than or equal to 80U/L, and the GGT score is 3.3 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 3.4 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.4 points;
B2) the liver cancer risk score is the age score, the AFP score, the DCP score, the GGT score, the PLT score, the WBC score and the ALB score, and the model is named as a liver cancer risk score model M01;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.6; the age is more than or equal to 60 and less than 65 years, and the age score is 3.9; the age is more than or equal to 65 years, and the age score is 3.7 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.9 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 3.5 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 5.3 points; the content is more than or equal to 400ng/mL, and the AFP score is 9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 2.5 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 6.6 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 10.3 points; the content is more than or equal to 120mAU/mL, and the DCP score is 12.8 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 3.2 points; the content of 45 is less than 80U/L, and the GGT score is 4.6 points; the content is more than or equal to 80U/L, and the GGT score is 3.4 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109L is not more than count < 150 x 109L, PLT score 1; counting<80*109L, PLT score 3.6 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.5 points;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 3.1 points;
B3) the liver cancer risk score is age score, AFP score, DCP score and PLT score, and the model is named as a liver cancer risk score model M04;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.0; the age is more than or equal to 60 and less than 65 years, and the age score is 2.5 points; the age is more than or equal to 65 years, and the age score is 2.2 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.3 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.7 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 3.7 points; the content is more than or equal to 400ng/mL, and the AFP score is 5.9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 1.5 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 4.4 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 6.4 points; the content is more than or equal to 120mAU/mL, and the DCP score is 8.6 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 3.0 points;
B4) the liver cancer risk score is age score, AFP score, DCP score, GGT score, WBC score and ALB score, and the model is named as a liver cancer risk score model M06
Wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.0; the age is more than or equal to 60 and less than 65 years, and the age score is 2.2 points; the age is more than or equal to 65 years, and the age score is 2.0;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 1.7 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.0 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 3.0 points; the content is more than or equal to 400ng/mL, and the AFP score is 4.9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 1.3 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 3.5 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 5.6 points; the content is more than or equal to 120mAU/mL, and the DCP score is 6.7 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 1.8 points; the content of 45 is less than 80U/L, and the GGT score is 2.5 points; the content is more than or equal to 80U/L, and the GGT score is 2.0 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.4 points;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 1.5 points;
B5) the liver cancer risk score is age score, AFP score, DCP score, GGT score, PLT score and ALB score, and the model is named as a liver cancer risk score model M07;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.4; the age is more than or equal to 60 and less than 65 years, and the age score is 3.3 points; the age is more than or equal to 65 years, and the age score is 3.2 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.4 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 3.0 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 4.6 points; the content is more than or equal to 400ng/mL, and the AFP score is 7.4 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 2.1 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 5.7 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 8.6 points; the content is more than or equal to 120mAU/mL, and the DCP score is 10.7 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 2.6 points; the content of 45 is less than 80U/L, and the GGT score is 3.9 points; the content is more than or equal to 80U/L, and the GGT score is 2.8 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 3.6 points;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, and the ALB content is less than 38g/L which is 0; the content is more than or equal to 38g/L and 2.5 min;
B6) the liver cancer risk score is age score, AFP score, DCP score, GGT score and WBC score, and the model is named as a liver cancer risk score model M09;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.0; the age is more than or equal to 60 and less than 65 years, and the age score is 2.1; the age is more than or equal to 65 years, and the age score is 1.9 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 1.5 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 1.7 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 2.5 points; the content is more than or equal to 400ng/mL, and the AFP score is 4.2 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 1.3 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 3.4 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 5.3 points; the content is more than or equal to 120mAU/mL, and the DCP score is 6.3 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 1.7 points; the content of 45 is less than 80U/L, and the GGT score is 2.3 points; the content is more than or equal to 80U/L, and the GGT score is 1.8 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.2 points;
B7) the liver cancer risk score is age score, AFP score, DCP score, GGT score and PLT score, and the model is named as a liver cancer risk score model M10;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.5 points; the age is more than or equal to 60 and less than 65 years, and the age score is 3.4; the age is more than or equal to 65 years, and the age score is 3.3 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content is more than or equal to 7 and less than 20ng/mL, and the AFP score is 2.3 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.8 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 4.2 points; the content is more than or equal to 400ng/mL, and the AFP score is 6.7 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 2.2 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 5.8 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 8.6 points; the content is more than or equal to 120mAU/mL, and the DCP score is 10.8 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 2.7 points; the content of 45 is less than 80U/L, and the GGT score is 3.8 points; the content is more than or equal to 80U/L, and the GGT score is 2.7 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 3.4 points;
B8) the liver cancer risk score is age score, AFP score, DCP score, GGT score, PLT score, WBC score, ALB score and cirrhosis score, and the model is named as a liver cancer risk score model CM 01;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 36.9 points; the age is more than or equal to 60 and less than 65 years, and the age score is 87.2; the age is more than or equal to 65 years, and the age score is 82.5 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 54.8 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 65.5 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 101.1 points; the content is more than or equal to 400ng/mL, and the AFP score is 194.9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 58.9 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 150 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 217; the content is more than or equal to 120mAU/mL, and the DCP score is 265.4 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content of 20 is less than 45U/L, and the GGT score is 52.8 points; the content of 45 is less than 80U/L, and the GGT score is 79.3 points; the content is more than or equal to 80U/L, and the GGT score is 68.9 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 38.5 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 16.7 points;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 72 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, the cirrhosis score is 106 points; if not, the cirrhosis score is 0;
B9) the liver cancer risk score is age score, AFP score, DCP score, GGT score, PLT score, WBC score and cirrhosis score, and the model is named as a liver cancer risk score model CM 02;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 30.1 points; the age is more than or equal to 60 and less than 65 years, and the age score is 63.4 points; the age is more than or equal to 65 years, and the age score is 63.5 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 39.7 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 44.0 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 64.6 points; the content is more than or equal to 400ng/mL, and the AFP score is 134.9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 46.4 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 115.2 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 160.7 points; the content is more than or equal to 120mAU/mL, and the DCP score is 197 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content of 20 is less than 45U/L, and the GGT score is 39.5 points; the content of 45 is less than 80U/L, and the GGT score is 57 points; the content is more than or equal to 80U/L, and the GGT score is 47 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 24.2 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 11.2 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, the cirrhosis score is 77.8 points; if not, the cirrhosis score is 0;
B10) the liver cancer risk score is age score, AFP score, DCP score, PLT score and cirrhosis score, and the model is named as a liver cancer risk score model CM 04;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 4.6 points; the age is more than or equal to 60 and less than 65 years, and the age score is 10.4 points; the age is more than or equal to 65 years, and the age score is 9.7 points;
the AFP score represents a score value corresponding to the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 8.5 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 9.1 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 12.1 points; the content is more than or equal to 400ng/mL, and the AFP score is 24.4 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 7.1 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 18.7 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 26.1 points; the content is more than or equal to 120mAU/mL, and the DCP score is 33.0 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 5.1 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, cirrhosis score 14.2 points; if not, the cirrhosis score is 0;
B11) the liver cancer risk score is age score, AFP score, DCP score, GGT score, WBC score, ALB score and cirrhosis score, and the model is named as a liver cancer risk score model CM 06;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.3; the age is more than or equal to 60 and less than 65 years, and the age score is 3.0; the age is more than or equal to 65 years, and the age score is 2.7 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, wherein the AFP is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 1.9 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.1 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 3.4 points; the content is more than or equal to 400ng/mL, and the AFP score is 6.4 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 1.9 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 5.0 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 7.3 points; the content is more than or equal to 120mAU/mL, and the DCP score is 8.7 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 1.8 points; the content of 45 is less than 80U/L, and the GGT score is 2.6 points; the content is more than or equal to 80U/L, and the GGT score is 2.3 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.0 point;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 2.2 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, cirrhosis score 3.7 points; if not, the cirrhosis score is 0;
B12) the liver cancer risk score is age score, AFP score, DCP score, GGT score, PLT score, ALB score and cirrhosis score, and the model is named as a liver cancer risk score model CM 07;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 13.4 points; the age is more than or equal to 60 and less than 65 years, and the age score is 31.2 points; the age is more than or equal to 65 years, and the age score is 29.4;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, wherein the AFP is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 19.5 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 23.6 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 36.2 points; the content is more than or equal to 400ng/mL, and the AFP score is 68.4 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 20.6 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 53.3 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 76.5 points; the content is more than or equal to 120mAU/mL, and the DCP score is 93.4 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content of 20 is less than 45U/L, and the GGT score is 18.4 points; the content of 45 is less than 80U/L, and the GGT score is 28.0 points; the content is more than or equal to 80U/L, and the GGT score is 23.9 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 16.3 points;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 25.1 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: is, cirrhosis score 38 points; if not, the cirrhosis score is 0;
B13) the liver cancer risk score is age score, AFP score, DCP score, GGT score, WBC score and cirrhosis score, and the model is named as a liver cancer risk score model CM 09;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.6; the age is more than or equal to 60 and less than 65 years, and the age score is 3.3 points; the age is more than or equal to 65 years, and the age score is 3.2 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, wherein the AFP is less than 7ng/mL, and the AFP score is 0; the content is more than or equal to 7 and less than 20ng/mL, and the AFP score is 2.1 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.2 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 3.3 points; the content is more than or equal to 400ng/mL, and the AFP score is 6.8 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 2.3 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 5.9 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 8.2 points; the content is more than or equal to 120mAU/mL, and the DCP score is 9.9 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 2.0 points; the content of 45 is less than 80U/L, and the GGT score is 2.9 points; the content is more than or equal to 80U/L, and the GGT score is 2.4 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; content (wt.)<4*106L, WBC score 1.0 point;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, cirrhosis score 4.1 points; if not, the cirrhosis score is 0;
B14) the liver cancer risk score is age score, AFP score, DCP score, GGT score, PLT score and cirrhosis score, and the model is named as a liver cancer risk score model CM 10;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 14; the age is more than or equal to 60 and less than 65 years, and the age score is 29.2 points; the age is more than or equal to 65 years, and the age score is 29.1;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, wherein the AFP is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 18.1 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 20.4 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 30.0 points; the content is more than or equal to 400ng/mL, and the AFP score is 61.2 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 20.9 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 52.7 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 72.9 points; the content is more than or equal to 120mAU/mL, and the DCP score is 89.3 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content of 20 is less than 45U/L, and the GGT score is 17.8 points; the content of 45 is less than 80U/L, and the GGT score is 26 points; the content is more than or equal to 80U/L, and the GGT score is 20.9 points;
the PLT score represents the corresponding score of the PLT count within the corresponding value range: PLT count is not less than 150 x 109L, PLT score 0; 80*109L is not more than count < 150 x 109L, PLT score 1; counting<80*109L, PLT score 13.3 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if, cirrhosis score 35.9 points; no, cirrhosis score was 0.
Further, the judgment criteria for the risk level of liver cancer in the subject are as follows:
C1) the risk grade interpretation standard of the liver cancer risk model M02 is as follows: p is less than or equal to 0.0072, which is low risk; p is more than 0.0072 and less than or equal to 0.0319, and is medium-high risk; p >0.0319 is at very high risk;
C2) the risk grade interpretation standard of the liver cancer risk scoring model M02 is as follows: the score is less than or equal to 5.0, and the low risk is divided; the score is more than 5.0 and less than or equal to 9.0, the risk is medium and high; score >9.0 is extremely high risk;
C3) the risk grade interpretation standard of the liver cancer risk model M01 is as follows: p is less than or equal to 0.0068, which is low risk; p is more than 0.0068 and less than or equal to 0.0289, which is medium-high risk; p is more than 0.0289 and is extremely high risk;
C4) the risk grade interpretation standard of the liver cancer risk scoring model M01 is as follows: the score is less than or equal to 8.1, and the low risk is divided; the score is more than 8.1 and less than or equal to 11.7, the risk is medium-high; score >11.7 is very high risk;
C5) the risk grade interpretation standard of the liver cancer risk model M04 is as follows: p is less than or equal to 0.0071, which is low risk; p is more than 0.0071 and less than or equal to 0.0283, which is medium-high risk; p is more than 0.0283 and is extremely high risk;
C6) the risk grade interpretation standard of the liver cancer risk scoring model M04 is as follows: the score is less than or equal to 1.8, and the low risk is divided; the score is more than 1.8 and less than or equal to 3.9, the risk is medium-high; score >3.9 is extremely high risk;
C7) the risk grade interpretation standard of the liver cancer risk model M06 is as follows: p is less than or equal to 0.0080, which is low risk; p is more than 0.0080 and less than or equal to 0.0319, and is medium-high risk; p >0.0319 is at very high risk;
C8) the risk grade interpretation standard of the liver cancer risk scoring model M06 is as follows: the score is less than or equal to 4.3, and the low risk is divided; the score is more than 4.3 and less than or equal to 6.1, the risk is medium-high; score >6.1 is extremely high risk;
C9) the risk grade interpretation standard of the liver cancer risk model M07 is as follows: p is less than or equal to 0.0077, which is low risk; p is more than 0.0077 and less than or equal to 0.0299, which is medium-high risk; p is more than 0.0299, which is extremely high risk;
C10) the risk grade interpretation standard of the liver cancer risk scoring model M07 is as follows: the score is less than or equal to 7.0, and the low risk is divided; the score is more than 7.0 and less than or equal to 9.7, the risk is medium-high; score >9.7 is very high risk;
C11) the risk grade interpretation standard of the liver cancer risk model M09 is as follows: p is less than or equal to 0.0077, which is low risk; p is more than 0.0077 and less than or equal to 0.0327, which is medium-high risk; score P >0.0327 is extremely high risk;
C12) the risk grade interpretation standard of the liver cancer risk scoring model M09 is as follows: the score is less than or equal to 2.6, and the low risk is divided; the score is more than 2.6 and less than or equal to 4.4, the risk is medium-high; scores >4.4 are classified as extremely high risk;
C13) the risk grade interpretation standard of the liver cancer risk model M10 is as follows: p is less than or equal to 0.0078, which is low risk; p is more than 0.0078 and less than or equal to 0.0306, which is medium-high risk; p is more than 0.0306, which is extremely high risk;
C14) the risk grade interpretation standard of the liver cancer risk scoring model M10 is as follows: the score is less than or equal to 4.6, and the low risk is divided; the score is more than 4.6 and less than or equal to 7.5, the risk is medium-high; score >7.5 is very high risk;
C15) the risk grade interpretation criteria of the liver cancer risk model CM01 are: p is less than or equal to 0.0036, which is low-risk; p is more than 0.0036 and less than or equal to 0.0250, which is medium-high risk; p is more than 0.0250, which is extremely high risk;
C16) the risk grade interpretation criteria of the liver cancer risk scoring model CM01 are: scoring less than or equal to 169 is classified as low risk; the score is more than 169 and less than or equal to 268, and the risk is high and medium; score >268 for extreme high risk;
C17) the risk grade interpretation criteria of the liver cancer risk model CM02 are: p is less than or equal to 0.0038, which is low-risk; p is more than 0.0038 and less than or equal to 0.0259, which is medium-high risk; p is more than 0.0259 is extremely high-risk;
C18) the risk grade interpretation criteria of the liver cancer risk scoring model CM02 are: the score is less than or equal to 77, and the low risk is divided; score of more than 77 and less than or equal to 149 is classified as medium-high risk; score >149 is very high risk;
C19) the risk grade interpretation criteria of the liver cancer risk model CM04 are: p is less than or equal to 0.0024, which is low risk; p is more than 0.0024 and less than or equal to 0.0254, which is medium-high risk; p is more than 0.0254, which is extremely high risk;
C20) the risk grade interpretation criteria of the liver cancer risk scoring model CM04 are: the score is less than or equal to 4.9, and the low risk is divided; the score is more than 4.9 and less than or equal to 19.8, the risk is medium-high; score >19.8 is very high risk;
C21) the risk grade interpretation criteria of the liver cancer risk model CM06 are: p is less than or equal to 0.0035, which is low-risk; p is more than 0.0035 and less than or equal to 0.0286, which is medium-high risk; p is more than 0.0286 is extremely high risk;
C22) the risk grade interpretation criteria of the liver cancer risk scoring model CM06 are: the score is less than or equal to 5.4, and the low risk is divided; the score is more than 5.4 and less than or equal to 9.0, the risk is medium and high; score >9.0 is extremely high risk;
C23) the risk grade interpretation criteria of the liver cancer risk model CM07 are: p is less than or equal to 0.0037, which is low-risk; p is more than 0.0037 and less than or equal to 0.0261, which is medium-high risk; p is more than 0.0261, which is extremely high risk;
C24) the risk grade interpretation criteria of the liver cancer risk scoring model CM07 are: scoring less than or equal to 60 points as low risk; the score is more than 60 and less than or equal to 95, the risk is high and medium; score >95 is extremely high risk;
C25) the risk grade interpretation criteria of the liver cancer risk model CM09 are: p is less than or equal to 0.0038, which is low-risk; p is more than 0.0038 and less than or equal to 0.0281, which is medium-high risk; p >0.0281 is at very high risk;
C26) the risk grade interpretation criteria of the liver cancer risk scoring model CM09 are: the score is less than or equal to 3.9, and the low risk is divided; the score is more than 3.9 and less than or equal to 7.7, the risk is medium-high; score >7.7 is very high risk;
C27) the risk grade interpretation criteria of the liver cancer risk model CM10 are: p is less than or equal to 0.0035, which is low-risk; p is more than 0.0035 and less than or equal to 0.0263, which is medium-high risk; p is more than 0.0263, which is extremely high risk;
C28) the risk grade interpretation criteria of the liver cancer risk scoring model CM10 are: the score is less than or equal to 33.7, and the low risk is divided; the score is more than 33.7 and less than or equal to 68.2, the risk is medium-high; scores >68.2 are very high risk.
In the use or the system, the evaluated persons are all male with HBsAg positive at age 35-69.
The above-mentioned subject to be evaluated satisfies the condition 1) HBsAg positive; 2) male, age 35-69 years, and not having either of the following: 1) liver cancer has been diagnosed clearly in the past; 2) suffering from hemorrhagic disorders or having hematemesis or hemoptysis on a recent day; 3) the general condition is extremely weak, and the life can not be managed by oneself; 4) severe cardiac and pulmonary dysfunction; 5) acute respiratory tract infection; 6) has suffered from other serious diseases and can not be tolerated or matched with subsequent examination; 7) have been diagnosed with other cancers.
The combined marker for predicting the liver cancer risk of the male hepatitis B virus infected person has the following characteristics: 1) all detection indexes are easy to be clinically implemented; 2) all the included parameters are objective laboratory quantitative detection values and are not influenced by subjective impression and experience of an individual; 3) the algorithm can realize personalized liver cancer risk analysis, and distinguish high-risk individuals with liver cancer within 1-2 years and low-risk individuals without liver cancer within 2 years. In the liver cancer high-risk patients, early warning can be realized 1-2 years before HCC nodules appear in imaging, the diagnosis and detection rate of the very early liver cancer (<3cm) is improved, meanwhile, the worry of a plurality of low-risk asymptomatic HBsAg positive patients is eliminated, and the monitoring and screening frequency of HCC is reduced. 4) From a public health perspective, cost-effective hierarchical screening can be achieved.
Drawings
FIG. 1 is a flow chart of general examination and laboratory testing of a subject.
FIG. 2 shows the risk of liver cancer accumulation in the high-risk, high-risk and low-risk groups after the Male-ABCD model grouping
A. Training a set; B. a verification set; C. implementation population-1; D. implementation population-2; E. people who practice the group-3.
Detailed Description
The present invention is described in further detail below with reference to specific embodiments, which are given for the purpose of illustration only and are not intended to limit the scope of the invention. The examples provided below serve as a guide for further modifications by a person skilled in the art and do not constitute a limitation of the invention in any way.
The experimental procedures in the following examples are conventional unless otherwise specified. Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Statement of ethics
Based on early HCC screening projects carried out in community groups, the inventor establishes community-based cohort research (CCOP-LC cohort; Chinese clinical registration, ChiCTR-EOC-17012835) on liver cancer high-risk groups in 2017. The study protocol (NCC201709011) was approved by the institutional review board of the national cancer center/national center for oncology clinical medicine research/oncology hospital of the chinese medical academy of sciences, beijing, china.
1. The study population of the following examples:
after inquiring personal hepatitis, tumor history and family history, measuring height, weight and waistline general physical examination, sampling blood through fingertips, and adopting HBsAg test paper to rapidly determine and analyze, the patients who meet the following conditions are included: 1) HBsAg positive; 2) male, age 35-69 years. With any one of the following exclusions: 1) liver cancer has been diagnosed clearly in the past; 2) suffering from hemorrhagic disorders or having hematemesis or hemoptysis on a recent day; 3) the general condition is extremely weak, and the life can not be managed by oneself; 4) severe cardiac and pulmonary dysfunction; 5) acute respiratory tract infection; 6) has suffered from other serious diseases and can not be tolerated or matched with subsequent examination; 7) have been diagnosed with other cancers.
In the following examples, a model training set was involved that contained 3629 asymptomatic HBsAg-positive adult males from anhui lingzhu, anhui moncheng and Jiangsu she yang; the validation set contained 963 asymptomatic HBsAg-positive adult males from sheng ju and han-pugion. The implementation was performed for 3 periods in the beginning of Jiangsu.
2. In the following examples, the collection of a peripheral venous blood sample
Blood collection items, blood sample treatment items and cryopreservation tubes were provided by the national cancer center, and the information is shown in table 1.
TABLE 1 manufacturer and product number of blood sampling article, blood sampling article and frozen tube used in laboratory test analysis
3. The reagents and consumables used in the assays described in the following examples are shown in Table 2.
TABLE 2 reagents, manufacturers and goods numbers used in laboratory test analyses
4. The following examples are the treatment of blood samples after collection and the examination of clinical laboratory criteria immediately at the site of collection:
during detection, laboratory detection reagents of all project points are uniform, but all project points are required to be purchased by themselves. The specific information is shown in Table 2.
1) Fully and evenly mixing the EDTA anticoagulated 2mL blood collection tube for 8 times, immediately finishing the platelet count and the leukocyte count of peripheral blood on a full-automatic blood cell counter, and recording data.
2) Centrifuging the serum tube for 5 minutes, sucking serum, and immediately detecting the quantitative determination of ALT, AST, total protein and albumin on a full-automatic biochemical instrument; AFP was measured on a chemiluminescent immunoassay analyzer.
3) Centrifuging 10mL blood collection tubes subjected to EDTA anticoagulation treatment for 10 minutes at room temperature, sucking supernatant, and respectively filling 1.8mL of the tubes 1 and 2 and 0.5-1mL of the tubes 3; pipette 0.5mL of cells into tubes 4 and 5, respectively. The 5 blood sample tubes were immediately frozen in a-80 freezer. And (4) freezing and transporting to national cancer center (Beijing) by using dry ice within 1-3 months after blood collection.
The first step is as follows: before the sample is transported, the ice bags are flatly placed into a-80-degree refrigerator and frozen for more than 24 hours.
The second step is that: before filling the sample, a layer of dry ice is paved in the foam box, then the sample box is filled in the foam box, and then the periphery of the sample box is filled with the dry ice. Finally, an ice bag frozen by a-80 ℃ refrigerator is placed on the top layer of the specimen box, and a cover is covered. After filling the dry ice, the foam box must be tightly sealed to reduce volatilization.
The samples were transported to-80 freezer for storage immediately after arrival at the national cancer center.
5. Blood sample treatment and analysis of relevant experimental indices by the national cancer center in the following examples, comprising the steps of:
1) within 1 month after receiving the blood sample, plasma of tube 2 subjected to EDTA anticoagulation treatment was thawed, and HBsAg was measured on an Abeti i2000 immunochemiluminescence detector using an Abetis B surface antigen (HBsAg) measurement kit. For HBsAg positive patients, adopting a quantitative detection kit of (des gamma carboxy prothrombin, abbreviated as DCP, also known as protein induced by vitamin K sensitivity or antagnostist-II, abbreviated as PIVKA) to quantitatively detect DCP in an Abeli 2000 immune chemiluminescence detector, and adopting a quantitative detection kit of Roche AFP to quantitatively detect AFP in an electrochemical luminescence immunoassay analyzer of Roche cobalt e 601; GGT is measured on a Roche Cobas e601 biochemical analyzer by adopting a gamma-GGT detection kit, and numerical values are recorded.
2) Taking 10 mu L of plasma (multiple wells, 5 mu L of each well), adopting a Shengxiang HBV-DNA quantitative detection reagent, carrying out HBV-DNA quantitative determination on an ABI 7500 quantitative PCR instrument, and recording numerical values.
6. Follow-up of study and diagnosis of liver cancer:
from baseline to 18-24 months after entering, all members of entering groups are subjected to abdominal B-ultrasonic AFP detection for at least 2 times, and a high-risk group screening method (recorded in Qidong China's primary liver cancer onset risk factor and high-risk group screening analysis, China's evidence medical journal 2018.18(5): 428-.
Patients with clinical indexes meeting the surgical indications are subjected to liver cancer resection and are confirmed by pathology.
And carrying out enhanced CT or enhanced MRI (magnetic resonance imaging) imaging diagnosis on the B-ultrasonic and AFP negative patients by adopting 15% random sampling so as to eliminate the possibility of liver cancer missed diagnosis.
7. Model building, verification and implementation
1) 3629 male HBsAg-positive persons from Anhui Linbi, Anhui Mongolian city and Jiangsu Zhuyang are used as training sets, and 963 male HBsAg-positive persons from Henan Shenqin and Henan Picheng are used as verification sets, and questionnaire investigation (including age, BMI, smoking history, drinking history, diabetes, liver cancer family history and the like), physical examination and peripheral venous blood sample detection (detection indexes include AFP, ng/mL; DCP, mAU/mL; GGT, U/L; PLT,109/L；WBC,106,/L and ALB, g/L). And the total number of HCC occurrences (incidence) within 2 years after baseline detection was counted and the results are shown in table 3.
TABLE 3 basic characteristics of baseline levels of subjects in training and validation sets (%)
2) In 3629 cases of male HBsAg-positive persons in the training set, the relation between objective indexes (in a continuous variable form) obtained by laboratory detection and the outcome of liver cancer within 1-2 years is determined by adopting single-factor and multi-factor Logistic regression analysis, and indexes capable of predicting the recent risk of liver cancer of the male HBsAg-positive persons are screened. See table 4.
TABLE 4 analysis of Single and Multi-factor Logistic regression analysis of 3629 HBsAg-positive males on training set
Entering variable with P value <0.1 in single-factor Logistic regression into multi-factor Logistic regression analysis
3) For convenience of application, variables with statistical significance (P-value <0.05) in multi-factor Logistic regression are converted into grade variables according to the incidence rates of liver cancer corresponding to different value ranges. See table 5.
TABLE 5 incidence of liver cancer corresponding to each parameter in different value ranges
4) Combining the variables in a grade variable form, constructing a plurality of multi-factor Logistic regression models, drawing ROC curves (receiver operating regression curves), and comparing the differentiation degree of the plurality of models on the liver cancer occurrence risk (AUC) within 1-2 years after detection, which is shown in Table 6.
TABLE 6 differentiation of liver cancer onset in 1-2 years by model constructed after combination of different parameters
As can be seen from Table 6, the combined models with different parameters have certain improvement after being added with the index of B-ultrasonic diagnosis of liver cirrhosis, but the improvement is not obvious, and the purpose of better risk assessment can be achieved only by adopting laboratory detection indexes. The diagnosis of liver cirrhosis under B-ultrasonic is greatly influenced by the subjective experience of a B-ultrasonic doctor, the laboratory detection index is more objective and is easy to develop in areas with different medical conditions, and whether the liver cirrhosis index for B-ultrasonic diagnosis is increased or not can be considered according to actual conditions when the model is used.
5) In order to realize liver cancer risk stratification, the prediction probability corresponding to the sensitivity of 98.5% on the ROC curve is used as a cutoff value of a high-risk group and a low-risk group, the prediction probability corresponding to the positive prediction value of 22.5% is used for further dividing the high-risk group into a high-risk group and a medium-high-risk group, and the stratification efficiency of each model in a training set is analyzed (indexes include: the occupation ratio of the extremely-high-risk, medium-high-risk and low-risk groups is high; sensitivity of the high-risk group, positive predictive value of the extremely-high-risk group, negative predictive value of the low-risk group, and area under ROC curve of each model) and selecting a parameter combination with optimal layering effect as a final model. See table 7.
TABLE 7 stratification and prediction of HBsAg-positive Male liver cancer Risk for different models
Remarking: three variables in M03, age, AFP, DCP, are variables in the GALAD model for HCC diagnosis, in addition to which GALAD is also incorporated AFP-L3, see reference 1 Johnson PJ, et al. 23: 144-53; reference 2 to Berhane S, et al, clin Gastroenterol Hepatol 2016; 14:875-86e 6.
A stratified model of HBsAg-positive adult Male's risk of developing liver cancer within 1-2 years using model M02 in Table 7, referred to as Male-ABCD, has regression coefficients as shown in Table 8.
TABLE 8 beta regression coefficients and score scaling for Male-ABCD models in training set
Remarking: the regression coefficient of the reference group was 0, and the regression coefficients were calculated by comparing the other groups with the reference group.
The score cutoff value of the extremely-high-risk and medium-high-risk groups is 9.0 points, and the score cutoff value of the medium-high-risk and low-risk groups is 5.0 points.
Formula of Male-ABCD liver cancer risk assessment model (liver cancer risk assessment model M02): risk of liver cancer (P) ═ ex/(1+ex) (ii) a x ═ 7.221+ β (age) + β (AFP) + β (DCP) + β (GGT) + β (PLT) + β (WBC);
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; when the age is less than 60 years and is not less than 45, beta (age) is 0.765; when the age is more than or equal to 60 and less than 65 years, the beta (age) is 1.668; when the age is more than or equal to 65 years, beta (age) is 1.62;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the AFP content is more than or equal to 7 and less than 20ng/mL, and the beta (AFP) is 1.162; the content of AFP is more than or equal to 20 and less than 80ng/mL, and the content of beta (AFP) is 1.335; the AFP content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.003; the AFP content is more than or equal to 400ng/mL, and the beta (AFP) is 3.432;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.125; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.897; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.332; the content is more than or equal to 120mAU/mL, beta (DCP) is 5.458
Wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.348; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.923; the content is more than or equal to 80U/L, and the beta (GGT) is 1.381;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, and the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ] 0.423; counting<80*109/L，β(PLT)＝1.434
Wherein β (WBC) represents the corresponding regression coefficient of WBC count in the corresponding value range, WBC: count is not less than 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.612；
For the liver cancer risk assessment model M02, the risk grade interpretation standard is as follows: p is less than or equal to 0.0072, which is low risk; p is more than 0.0072 and less than or equal to 0.0319, and is medium-high risk; p >0.0319 is at very high risk.
For convenient application, dividing the regression coefficient corresponding to each variable in the model in the corresponding value range by the minimum regression coefficient in the model as a score, and converting the Male-ABCD into a risk scoring model M02, wherein the liver cancer risk score is age score + AFP score + DCP score + GGT score + PLT score + WBC score
Score for each index in the scoring model:
age: the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.8; the age is more than or equal to 60 and less than 65 years, and the age score is 3.9; the age is more than or equal to 65 years, and the age score is 3.8 points;
AFP: the content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.7 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 3.2 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 4.7 points; the content is more than or equal to 400ng/mL, and the AFP score is 8.1 points;
DCP: the content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 2.7 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 6.8 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 10.2 points; the content is more than or equal to 120mAU/mL, and the DCP score is 12.9 points;
GGT: the content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 3.2 points; the content of 45 is less than 80U/L, and the GGT score is 4.5 points; the content is more than or equal to 80U/L, and the GGT score is 3.3 points;
PLT: the content is more than or equal to 150 x 109L, PLT score 0; 80*109The content of L is less than or equal to 150 x 109L, PLT score 1; content (c) of<80*109L, PLT score 3.4 points;
WBC: the content is more than or equal to 4 x 106L, WBC score 0; content (wt.)<4*106L, WBC score 1.4 points;
for the liver cancer risk scoring model M02, the risk grade interpretation standard is as follows: the score is less than or equal to 5.0, and the low risk is divided; the score is more than 5.0 and less than or equal to 9.0, the risk is medium and high; scores >9.0 are very high risk.
In addition to the aforementioned M02, each model referred to in table 7 is specifically as follows:
liver cancer risk assessment model M01 (including variables: age, AFP, DCP, GGT, PLT, WBC, ALB) liver cancer risk (P) ═ ex/(1+ex) (ii) a x ═ 8.484+ β (age) + β (AFP) + β (DCP) + β (GGT) + β (PLT) + β (WBC) + β (ALB);
regression coefficient (β) corresponding to each index detection result in the M01 model:
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.699; 60 is less than 65 years old, beta (age) is 1.665; age is more than or equal to 65 years, beta (age) is 1.595;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.217; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.471; the content of 80 is less than or equal to 400ng/mL, and beta (AFP) is 2.263; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.850;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.057; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.821; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.376; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.447;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.348; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.979; the content is more than or equal to 80U/L, and beta (GGT) is 1.463;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, and the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ] 0.426; counting<80*109/L，β(PLT)＝1.527；
Wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, and the WBC count is not less than 4 x 106L,. beta. (WBC) ═ 0; WBC count<4*106/L，β(WBC)＝0.651；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.325;
risk rating interpretation criteria: p is less than or equal to 0.0068, which is low risk; p is more than 0.0068 and less than or equal to 0.0289, which is medium-high risk; p >0.0289 is extremely high risk.
The liver cancer risk assessment model M01 was transformed into a risk scoring model M01, the liver cancer risk score being age score + AFP score + DCP score + GGT score + PLT score + WBC score + ALB score.
Score for each index in the scoring model:
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.6; the age is more than or equal to 60 and less than 65 years, and the age score is 3.9; the age is more than or equal to 65 years, and the age score is 3.7 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.9 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 3.5 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 5.3 points; the content is more than or equal to 400ng/mL, and the AFP score is 9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 2.5 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 6.6 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 10.3 points; the content is more than or equal to 120mAU/mL, and the DCP score is 12.8 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 3.2 points; the content of 45 is less than 80U/L, and the GGT score is 4.6 points; the content is more than or equal to 80U/L, and the GGT score is 3.4 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 3.6 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.5 points;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 3.1 points;
risk rating interpretation criteria: the score is less than or equal to 8.1, and the low risk is divided; the score is more than 8.1 and less than or equal to 11.7, the risk is medium-high; scores >11.7 are very high risk.
Liver cancer risk model M04 (including variables: age, AFP, DCP, PLT)
Risk of liver cancer (P) ═ ex/(1+ex)
x ═ 6.091+ β (age) + β (AFP) + β (DCP) + β (PLT)
Regression coefficient (β) corresponding to each index detection result in the M04 model:
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years, and the beta (age) is 0; age is not less than 45 and less than 60 years, beta (age) is 0.638; 60 is less than or equal to age 65, beta (age) is 1.594; age is more than or equal to 65 years, beta (age) is 1.424;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and beta (AFP) is 1.459; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.715; the content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.337; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.740;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content is more than or equal to 20 and less than 40mAU/mL, and the beta (DCP) is 0.988; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.790; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.114; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.506;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, and the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ] 0.659; counting<80*109/L，β(PLT)＝1.887；
Risk rating interpretation criteria: p is less than or equal to 0.0071, which is low risk; p is more than 0.0071 and less than or equal to 0.0283, which is medium-high risk; p >0.0283 is extremely high risk.
Converting M04 into a risk scoring system, wherein the liver cancer risk score is age score + AFP score + DCP score + PLT score, and the model is named as a liver cancer risk scoring model M04;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.0; the age is more than or equal to 60 and less than 65 years, and the age score is 2.5 points; the age is more than or equal to 65 years, and the age score is 2.2 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.3 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.7 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 3.7 points; the content is more than or equal to 400ng/mL, and the AFP score is 5.9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 1.5 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 4.4 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 6.4 points; the content is more than or equal to 120mAU/mL, and the DCP score is 8.6 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 3.0 points;
risk rating interpretation criteria: the score is less than or equal to 1.8, and the low risk is divided; the score is more than 1.8 and less than or equal to 3.9, the risk is medium-high; 3.9 is extremely high risk
Liver cancer risk model M06 (including variables: age, AFP, DCP, GGT, WBC, ALB)
Risk of liver cancer (P) ═ ex/(1+ex)
x ═ 8.293+ β (age) + β (AFP) + β (DCP) + β (GGT) + β (WBC) + β (ALB)
Regression coefficient (β) corresponding to each index detection result in the M06 model:
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is not less than 45 and less than 60 years, beta (age) is 0.810; age 60 is less than 65 years, beta (age) is 1.798; age is more than or equal to 65 years, beta (age) is 1.608;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.382; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.632; the content of 80 is less than or equal to 400ng/mL, and beta (AFP) is 2.408; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.979;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.023; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.850; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.558; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.401;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.477; the content of 45 is less than or equal to 80U/L, and the beta (GGT) is 2.050; the content is more than or equal to 80U/L, and the beta (GGT) is 1.598;
wherein,beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, and when the WBC count is more than or equal to 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝1.129；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB content is less than 38g/L, the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.216;
risk rating interpretation criteria: p is less than or equal to 0.0080, which is low risk; p is more than 0.0080 and less than or equal to 0.0319, and is medium-high risk; p >0.0319 is at very high risk.
Converting M06 into a risk scoring system, wherein the liver cancer risk score is age score + AFP score + DCP score + GGT score + WBC score + ALB score, and the model is named as a liver cancer risk scoring model M06
Wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.0; the age is more than or equal to 60 and less than 65 years, and the age score is 2.2 points; the age is more than or equal to 65 years, and the age score is 2.0;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 1.7 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.0 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 3.0 points; the content is more than or equal to 400ng/mL, and the AFP score is 4.9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 1.3 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 3.5 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 5.6 points; the content is more than or equal to 120mAU/mL, and the DCP score is 6.7 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 1.8 points; the content of 45 is less than 80U/L, and the GGT score is 2.5 points; the content is more than or equal to 80U/L, and the GGT score is 2.0 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106Evaluation of/L, WBC0 point; counting<4*106L, WBC score 1.4 points;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 1.5 points;
risk rating interpretation criteria: the score is less than or equal to 4.3, and the low risk is divided; the score is more than 4.3 and less than or equal to 6.1, the risk is medium-high; scores >6.1 are very high risk.
Liver cancer risk model M07 (including variables: age, AFP, DCP, GGT, PLT, ALB):
risk of liver cancer (P) ═ ex/(1+ex)
x ═ 8.384+ β (age) + β (AFP) + β (DCP) + β (GGT) + β (PLT) + β (ALB)
Regression coefficient (β) corresponding to each index detection result in M07 model:
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.701; 60 is less than or equal to age 65, beta (age) is 1.672; the age is more than or equal to 65 years, and beta (age) is 1.603;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.221; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.498; the content of 80 is less than or equal to 400ng/mL, and beta (AFP) is 2.346; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.743;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.041; the content of 40 is less than or equal to 50mAU/mL, and beta (DCP) is 2.856; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.353; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.407;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and the beta (GGT) is 1.321; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.981; the content is more than or equal to 80U/L, and beta (GGT) is 1.433;
wherein β (PLT) represents PLT countWhen the PLT count is not less than 150 x 10, the corresponding regression coefficient in the corresponding value range9/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ═ 0.505; counting<80*109/L，β(PLT)＝1.805；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB: the content is <38g/L, beta (ALB) ═ 0; the content is more than or equal to 38g/L, and the beta (ALB) is 1.284;
risk rating interpretation criteria: p is less than or equal to 0.0077, which is low risk; p is more than 0.0077 and less than or equal to 0.0299, which is medium-high risk; p is more than 0.0299, which is extremely high-risk.
Converting M07 into a risk scoring system, wherein the liver cancer risk score is age score + AFP score + DCP score + GGT score + PLT score + ALB score, and the model is named as a liver cancer risk scoring model M07;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.4; the age is more than or equal to 60 and less than 65 years, and the age score is 3.3 points; the age is more than or equal to 65 years, and the age score is 3.2 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.4 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 3.0 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 4.6 points; the content is more than or equal to 400ng/mL, and the AFP score is 7.4 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content is more than or equal to 20 and less than 40mAU/mL, and the DCP score is 2.1 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 5.7 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 8.6 points; the content is more than or equal to 120mAU/mL, and the DCP score is 10.7 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 2.6 points; the content of 45 is less than 80U/L, and the GGT score is 3.9 points; the content is more than or equal to 80U/L, and the GGT score is 2.8 points;
the PLT score indicates that the PLT count is within the corresponding range of valuesInner corresponding score, PLT count ≥ 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 3.6 points;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, and the ALB content is less than 38g/L which is 0; the content is more than or equal to 38g/L and 2.5 min;
risk rating interpretation criteria: the score is less than or equal to 7.0, and the low risk is divided; the score is more than 7.0 and less than or equal to 9.7, the risk is medium-high; scores >9.7 were very high risk.
Liver cancer risk model M09 (including variables: age, AFP, DCP, GGT, WBC)
Risk of liver cancer (P) ═ ex/(1+ex)
x ═ 7.115+ β (age) + β (AFP) + β (DCP) + β (GGT) + β (WBC)
Regression coefficient (β) corresponding to each index detection result in the M09 model:
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.857; 60 is less than or equal to age 65, beta (age) is 1.781; the age is more than or equal to 65 years, and beta (age) is 1.616;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.323; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.492; the content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.165; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.579;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.079; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.917; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.499; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.428;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and the beta (GGT) is 1.466; the content of 45 is less than or equal to 80U/L, and the beta (GGT) is 2.000; the content is more than or equal to 80U/L, and beta (GGT) is 1.520;
wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is more than or equal to 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝1.061；
Risk rating interpretation criteria: p is less than or equal to 0.0077, which is low risk; p is more than 0.0077 and less than or equal to 0.0327, which is medium-high risk; p >0.0327 is extremely high risk.
Converting M09 into a risk scoring system, wherein the liver cancer risk score is age score + AFP score + DCP score + GGT score + WBC score, and the model is named as a liver cancer risk scoring model M09;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.0; the age is more than or equal to 60 and less than 65 years, and the age score is 2.1; the age is more than or equal to 65 years, and the age score is 1.9 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content is more than or equal to 7 and less than 20ng/mL, and the AFP score is 1.5 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 1.7 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 2.5 points; the content is more than or equal to 400ng/mL, and the AFP score is 4.2 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 1.3 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 3.4 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 5.3 points; the content is more than or equal to 120mAU/mL, and the DCP score is 6.3 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 1.7 points; the content of 45 is less than 80U/L, and the GGT score is 2.3 points; the content is more than or equal to 80U/L, and the GGT score is 1.8 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.2 points;
risk rating interpretation criteria: the score is less than or equal to 2.6, and the low risk is divided; p is more than 2.6 and less than or equal to 4.4, and the medium-high risk is divided into medium-high risk; p >4.4 is classified as extremely high risk.
Liver cancer risk model M10 (including variables: age, AFP, DCP, GGT, PLT)
Risk of liver cancer (P) ═ ex/(1+ex)
x ═ 7.162+ β (age) + β (AFP) + β (DCP) + β (GGT) + β (PLT)
Regression coefficients corresponding to detection results of all indexes in the M10 model are as follows:
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.762; 60 is less than 65 years old, beta (age) is 1.678; the age is more than or equal to 65 years, and beta (age) is 1.633;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and beta (AFP) is 1.161; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.376; the content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.093; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.350;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.105; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.920; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.304; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.411;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.327; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.924; the content is more than or equal to 80U/L, and the beta (GGT) is 1.350;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109PLT count/L ≦<150*109L, [ beta ] (PLT) ═ 0.500; PLT counting<80*109/L，β(PLT)＝1.696；
Risk rating interpretation criteria: p is less than or equal to 0.0078, which is low risk; p is more than 0.0078 and less than or equal to 0.0306, which is medium-high risk; p is more than 0.0306, which is extremely high risk.
Converting M10 into a risk scoring system, wherein the liver cancer risk score is age score + AFP score + DCP score + GGT score + PLT score, and the model is named as a liver cancer risk scoring model M10;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.5 points; the age is more than or equal to 60 and less than 65 years, and the age score is 3.4; the age is more than or equal to 65 years, and the age score is 3.3 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.3 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.8 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 4.2 points; the content is more than or equal to 400ng/mL, and the AFP score is 6.7 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 2.2 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 5.8 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 8.6 points; the content is more than or equal to 120mAU/mL, and the DCP score is 10.8 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 2.7 points; the content of 45 is less than 80U/L, and the GGT score is 3.8 points; the content is more than or equal to 80U/L, and the GGT score is 2.7 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 3.4 points;
risk rating interpretation criteria: the score is less than or equal to 4.6, and the low risk is divided; the score is more than 4.6 and less than or equal to 7.5, the risk is medium-high; scores >7.5 are very high risk.
Liver cancer risk model CM01 (including variables: age, AFP, DCP, GGT, PLT, WBC, ALB, cirrhosis)
Risk of liver cancer (P) ═ ex/(1+ex)
x ═ 8.988+ β (age) + β (AFP) + β (DCP) + β (GGT) + β (PLT) + β (WBC) + β (ALB) + β (cirrhosis)
Regression coefficient (β) corresponding to each index detection result in the CM01 model:
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.734; 60 is less than or equal to age 65, beta (age) is 1.734; the age is more than or equal to 65 years, and beta (age) is 1.640;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.090; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.302; the content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.011; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.875;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.170; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.982; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.313; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.277;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content is more than or equal to 20 and less than 45U/L, and the beta (GGT) is 1.049; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.576; the content is more than or equal to 80U/L, and the beta (GGT) is 1.371;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ] 0.020; counting<80*109/L，β(PLT)＝0.766；
Wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is more than or equal to 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.333；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB content is less than 38g/L, the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.431;
wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: is, β (cirrhosis) ═ 2.108; no, β (cirrhosis) is 0;
risk rating interpretation criteria: p is less than or equal to 0.0036, which is low risk; p is more than 0.0036 and less than or equal to 0.0250, which is medium-high risk; p >0.0250 is extremely high risk.
Converting CM01 into a risk scoring system, wherein the liver cancer risk score is age score + AFP score + DCP score + GGT score + PLT score + WBC score + ALB score + cirrhosis score, and the model is named as a liver cancer risk scoring model CM 01;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 36.9 points; the age is more than or equal to 60 and less than 65 years, and the age score is 87.2; the age is more than or equal to 65 years, and the age score is 82.5 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 54.8 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 65.5 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 101.1 points; the content is more than or equal to 400ng/mL, and the AFP score is 194.9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 58.9 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 150 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 217; the content is more than or equal to 120mAU/mL, and the DCP score is 265.4 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content of 20 is less than 45U/L, and the GGT score is 52.8 points; the content of 45 is less than 80U/L, and the GGT score is 79.3 points; the content is more than or equal to 80U/L, and the GGT score is 68.9 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109L is not more than count150*109L, PLT score 1; counting<80*109L, PLT score 38.5 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score ═ 0 score; counting<4*106L, WBC score 16.7 points;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 72 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, the cirrhosis score is 106 points; if not, the cirrhosis score is 0;
risk rating interpretation criteria: the score is less than or equal to 169, and the score is low risk; the score is more than 169 and less than or equal to 268, and the risk is high and medium; score >268 was classified as very high risk.
Liver cancer risk model CM02 (including variables: age, AFP, DCP, GGT, PLT, WBC, cirrhosis)
Risk of liver cancer (P) ═ ex/(1+ex)
x ═ 7.627+ β (age) + β (AFP) + β (DCP) + β (GGT) + β (PLT) + β (WBC) + β (cirrhosis)
Regression coefficient (beta) corresponding to each index detection result in model
Wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.806; 60 is less than or equal to age 65, beta (age) is 1.699; age is more than or equal to 65 years, beta (age) is 1.701;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and beta (AFP) is 1.063; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.179; the content of 80 is less than or equal to 400ng/mL, and the beta (AFP) is 1.732; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.614;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.242; the content of 40 is less than or equal to 50mAU/mL, and beta (DCP) is 3.086; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.305; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.277;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.057; the content of 45 is less than or equal to 80U/L, and the beta (GGT) is 1.528; the content is more than or equal to 80U/L, and beta (GGT) is 1.258;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ] 0.027; counting<80*109/L，β(PLT)＝0.647；
Wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is more than or equal to 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.301；
Wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: β (cirrhosis) ═ 2.084; no, β (cirrhosis) is 0;
risk rating interpretation criteria: p is less than or equal to 0.0038, which is low-risk; p is more than 0.0038 and less than or equal to 0.0259, which is medium-high risk; p >0.0259 is extremely high risk.
For convenience of application, CM02 was converted into a risk scoring system, liver cancer risk score-age score + AFP score + DCP score + GGT score + PLT score + WBC score + cirrhosis score, and this model was named liver cancer risk scoring model CM 02;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 30.1 points; the age is more than or equal to 60 and less than 65 years, and the age score is 63.4 points; the age is more than or equal to 65 years, and the age score is 63.5 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 39.7 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 44.0 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 64.6 points; the content is more than or equal to 400ng/mL, and the AFP score is 134.9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 46.4 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 115.2 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 160.7 points; the content is more than or equal to 120mAU/mL, and the DCP score is 197 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content of 20 is less than 45U/L, and the GGT score is 39.5 points; the content of 45 is less than 80U/L, and the GGT score is 57 points; the content is more than or equal to 80U/L, and the GGT score is 47 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 24.2 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 11.2 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, the cirrhosis score is 77.8 points; if not, the cirrhosis score is 0;
risk rating interpretation criteria: the score is less than or equal to 77, and the low risk is divided; score of more than 77 and less than or equal to 149 is classified as medium-high risk; scores >149 were very high risk.
Liver cancer risk model CM04 (including variables: age, AFP, DCP, PLT, liver cirrhosis)
Risk of liver cancer (P) ex/(1+ex)
x ═ 4.541+ β (age) + β (AFP) + β (DCP) + β (PLT) + β (cirrhosis)
Regression coefficient (β) corresponding to each index detection result in the CM04 model:
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.738; 60 is less than or equal to age 65, beta (age) is 1.676; the age is more than or equal to 65 years, and beta (age) is 1.550;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content is more than or equal to 7 and less than 20ng/mL, and the beta (AFP) is 1.362; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.466; the content of 80 is less than or equal to 400ng/mL, and the beta (AFP) is 1.937; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.912;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.143; the content of 40 is less than or equal to 50mAU/mL, and the beta (DCP) is 3.000; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.188; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.301;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ═ 0.160; counting<80*109/L，β(PLT)＝0.813；
Wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: is, β (cirrhosis) ═ 2.286; no, β (cirrhosis) is 0;
risk rating interpretation criteria: p is less than or equal to 0.0024, which is low risk; p is more than 0.0024 and less than or equal to 0.0254, which is medium-high risk; p >0.0254 is extremely high risk.
Converting CM04 into a risk scoring system, wherein the liver cancer risk score is age score + AFP score + DCP + PLT + cirrhosis, and the model is named as a liver cancer risk scoring model CM 04;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 4.6 points; the age is more than or equal to 60 and less than 65 years, and the age score is 10.4 points; the age is more than or equal to 65 years, and the age score is 9.7 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 8.5 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 9.1 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 12.1 points; the content is more than or equal to 400ng/mL, and the AFP score is 24.4 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 7.1 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 18.7 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 26.1 points; the content is more than or equal to 120mAU/mL, and the DCP score is 33.0 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 5.1 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, cirrhosis score 14.2 points; if not, the cirrhosis score is 0;
risk rating interpretation criteria: the score is less than or equal to 4.9, and the low risk is divided; p is more than 4.9 and less than or equal to 19.8, and is classified as medium-high risk; p >19.8 is extremely high risk
Liver cancer risk model CM06 (including variables: age, AFP, DCP, GGT, WBC, ALB, liver cirrhosis)
Risk of liver cancer (P) ex/(1+ex)
x ═ 6.681+ β (age) + β (AFP) + β (DCP) + β (GGT) + β (WBC) + β (ALB) + β (cirrhosis)
Regression coefficient (β) corresponding to each index detection result in the CM06 model:
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.781; 60 is less than or equal to age 65 years, beta (age) is 1.800; the age is more than or equal to 65 years, and beta (age) is 1.635;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.133; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.282; the content of 80 is less than or equal to 400ng/mL, and the beta (AFP) is 2.014; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.841;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.166; the content of 40 is less than or equal to 50mAU/mL, and beta (DCP) is 3.015; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.362; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.219;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and the beta (GGT) is 1.065; the content of 45 is less than or equal to 80U/L, and the beta (GGT) is 1.540; the content is more than or equal to 80U/L, and the beta (GGT) is 1.378;
wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is more than or equal to 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.600；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB content is less than 38g/L, the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.328;
wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: β (cirrhosis) ═ 2.215; no, β (cirrhosis) is 0;
risk rating interpretation criteria: p is less than or equal to 0.0035, which is low-risk; p is more than 0.0035 and less than or equal to 0.0286, which is medium-high risk; p >0.0286 is extremely high risk.
Converting CM06 into a risk scoring system, wherein the liver cancer risk score is age score + AFP score + DCP score + GGT score + WBC score + ALB score + cirrhosis score, and the model is named as a liver cancer risk scoring model CM 06;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.3; the age is more than or equal to 60 and less than 65 years, and the age score is 3.0; the age is more than or equal to 65 years, and the age score is 2.7 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, wherein the AFP is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 1.9 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.1 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 3.4 points; the content is more than or equal to 400ng/mL, and the AFP score is 6.4 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 1.9 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 5.0 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 7.3 points; the content is more than or equal to 120mAU/mL, and the DCP score is 8.7 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 1.8 points; the content of 45 is less than 80U/L, and the GGT score is 2.6 points; the content is more than or equal to 80U/L, and the GGT score is 2.3 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.0 point;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 2.2 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, cirrhosis score was 3.7 points; if not, the cirrhosis score is 0;
risk rating interpretation criteria: the score is less than or equal to 5.4, and the low risk is divided; the score is more than 5.4 and less than or equal to 9.0, the risk is medium and high; scores >9.0 are very high risk.
Liver cancer risk model CM07 (including variables: age, AFP, DCP, GGT, PLT, ALB, liver cirrhosis)
Risk of liver cancer (P) ═ ex/(1+ex)
x ═ 6.825+ β (age) + β (AFP) + β (DCP) + β (GGT) + β (PLT) + β (ALB) + β (cirrhosis)
Regression coefficient (β) corresponding to each index detection result in the CM07 model:
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; 45 is less than or equal to age of 60 years, beta (age) is 0.755; 60 is less than or equal to age 65, beta (age) is 1.752; age is greater than or equal to 65 years, beta (age) is 1.651
Wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.093; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.325; the content of 80 is less than or equal to 400ng/mL, and the beta (AFP) is 2.034; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.844;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content is more than or equal to 20 and less than 40mAU/mL, and beta (DCP) is 1.157; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.995; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.295; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.248;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content is more than or equal to 20 and less than 45U/L, and beta (GGT) is 1.035; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.573; the content is more than or equal to 80U/L, and the beta (GGT) is 1.343;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L,. beta. (PLT) ═ 0.056; counting<80*109/L，β(PLT)＝0.913；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB content is less than 38g/L, the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.411;
wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: β (cirrhosis) ═ 2.136; no, β (cirrhosis) is 0;
risk rating interpretation criteria: p is less than or equal to 0.0037, which is low-risk; p is more than 0.0037 and less than or equal to 0.0261, which is medium-high risk; p >0.0261 is extremely high risk.
Converting CM07 into a risk scoring system, wherein the liver cancer risk score is age score + AFP score + DCP score + GGT score + PLT score + ALB score + cirrhosis score, and the model is named as a liver cancer risk scoring model CM 07;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 13.4 points; the age is more than or equal to 60 and less than 65 years, and the age score is 31.2 points; the age is more than or equal to 65 years, and the age score is 29.4;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, wherein the AFP is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 19.5 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 23.6 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 36.2 points; the content is more than or equal to 400ng/mL, and the AFP score is 68.4 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 20.6 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 53.3 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 76.5 points; the content is more than or equal to 120mAU/mL, and the DCP score is 93.4 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 18.4 points; the content of 45 is less than 80U/L, and the GGT score is 28.0 points; the content is more than or equal to 80U/L, and the GGT score is 23.9 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 16.3 points;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 25.1 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, the cirrhosis score is 38; if not, the cirrhosis score is 0;
risk rating interpretation criteria: scoring less than or equal to 60 points as low risk; p is more than 60 and less than or equal to 95, and the medium-high risk is divided; p >95 is extremely high risk.
Liver cancer risk model CM09 (including variables: age, AFP, DCP, GGT, WBC, liver cirrhosis)
Risk of liver cancer (P) ═ ex/(1+ex)
x ═ 5.445+ β (age) + β (AFP) + β (DCP) + β (GGT) + β (WBC) + β (cirrhosis)
Regression coefficient (β) corresponding to each index detection result in the CM09 model:
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.836; age 60 is less than 65 years, beta (age) is 1.749; the age is more than or equal to 65 years, and beta (age) is 1.689;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.098; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.173; the content of 80 is less than or equal to 400ng/mL, and beta (AFP) is 1.751; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.607;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, when the DCP: content <20mAU/mL, β (DCP) ═ 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.232; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 3.114; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.439; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.237;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT: the content is <20U/L, and beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.076; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.509; the content is more than or equal to 80U/L, and the beta (GGT) is 1.275;
wherein, β (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when WBC: count is not less than 4 x 106L, [ beta ] (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.529；
Wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: is, β (cirrhosis) ═ 2.183; no, β (cirrhosis) is 0;
risk rating interpretation criteria: p is less than or equal to 0.0038, which is low-risk; p is more than 0.0038 and less than or equal to 0.0281, which is medium-high risk; p >0.0281 is at very high risk.
Converting CM09 into a risk scoring system, wherein the liver cancer risk score is age score + AFP score + DCP score + GGT score + WBC score + cirrhosis score, and the model is named as a liver cancer risk scoring model CM 09;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.6; the age is more than or equal to 60 and less than 65 years, and the age score is 3.3 points; the age is more than or equal to 65 years, and the age score is 3.2 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, wherein the AFP is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.1 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.2 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 3.3 points; the content is more than or equal to 400ng/mL, and the AFP score is 6.8 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 2.3 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 5.9 points; the content is more than or equal to 50 and less than 120mAU/mL, and the DCP score is 8.2 points; the content is more than or equal to 120mAU/mL, and the DCP score is 9.9 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 2.0 points; the content of 45 is less than 80U/L, and the GGT score is 2.9 points; the content is more than or equal to 80U/L, and the GGT score is 2.4 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.0 point;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, cirrhosis score 4.1 points; if not, the cirrhosis score is 0;
risk rating interpretation criteria: the score is less than or equal to 3.9, and the low risk is divided; the score is more than 3.9 and less than or equal to 7.7, the risk is medium-high; score >7.7 as very high risk
Liver cancer risk model CM10 (including variables: age, AFP, DCP, GGT, PLT, cirrhosis)
Risk of liver cancer (P) ═ ex/(1+ex)
x ═ 5.506+ β (age) + β (AFP) + β (DCP) + β (GGT) + β (PLT) + β (cirrhosis)
Regression coefficients corresponding to detection results of the indexes in the CM10 model are as follows:
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; 45 is less than or equal to age of 60 years, beta (age) is 0.822; 60 is less than or equal to age 65, beta (age) is 1.715; the age is more than or equal to 65 years, and beta (age) is 1.712;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.062; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.202; the content of 80 is less than or equal to 400ng/mL, and beta (AFP) is 1.765; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.596;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.227; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 3.095; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.286; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.246;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.046; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.527; the content is more than or equal to 80U/L, and beta (GGT) is 1.231;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L,. beta. (PLT) ═ 0.059; counting<80*109/L，β(PLT)＝0.780；
Wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: is, β (cirrhosis) ═ 2.109; no, β (cirrhosis) is 0;
risk rating interpretation criteria: p is less than or equal to 0.0035, which is low-risk; p is more than 0.0035 and less than or equal to 0.0263, which is medium-high risk; p >0.0263 is extremely high risk.
Converting CM10 into a risk scoring system, wherein the liver cancer risk score is age score, AFP score, DCP score, GGT score, PLT score and cirrhosis score, and the model is named as a liver cancer risk scoring model CM 10;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 14; the age is more than or equal to 60 and less than 65 years, and the age score is 29.2 points; the age is more than or equal to 65 years, and the age score is 29.1;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, wherein the AFP is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 18.1 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 20.4 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 30.0 points; the content is more than or equal to 400ng/mL, and the AFP score is 61.2 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 20.9 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 52.7 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 72.9 points; the content is more than or equal to 120mAU/mL, and the DCP score is 89.3 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content of 20 is less than 45U/L, and the GGT score is 17.8 points; the content of 45 is less than 80U/L, and the GGT score is 26 points; the content is more than or equal to 80U/L, and the GGT score is 20.9 points;
the PLT score represents the corresponding score of the PLT count within the corresponding value range: PLT count is not less than 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 13.3 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if, cirrhosis score 35.9 points; if not, the cirrhosis score is 0;
risk rating interpretation criteria: the score is less than or equal to 33.7, and the low risk is divided; the score is more than 33.7 and less than or equal to 68.2, the risk is medium-high; scores >68.2 are very high risk.
The BMI index can be added to the model for comprehensive evaluation.
6) Model layering and verification of prediction efficiency: in 963 HBsAg-positive adult males with completely different sources and habitats from the training set study object, the layering and prediction efficiency of the Male-ABCD model on the HCC occurrence probability within 2 years is verified, and the high-risk, medium-high-risk and low-risk group occupation ratio is high; the sensitivity of the high-risk group, the positive predictive value of the extremely high-risk group and the negative predictive value of the low-risk group are shown in the table 9.
TABLE 9 model of the combination of relevant parameters for risk stratification and predictive efficacy of HCC development in HBsAg-positive adult males
Remarking: three variables in M03, age, AFP, DCP, are variables in the GALAD model for HCC diagnosis, in addition to which GALAD is also incorporated AFP-L3, see reference 1 Johnson PJ, et al. 23: 144-53; reference 2 to Berhane S, et al, clin Gastroenterol Hepatol 2016; 14:875-86e6
7) Comparison of the Male-ABCD model with current professional recommended screening protocols. See tables 7 and 9.
8) The incidence of HBsAg-positive adult males after identification and stratification by the Male-ABCD model. See fig. 2.
9) To simplify the application, the regression coefficient with the smallest value in the Male-ABCD model is taken as a unit, all the regression coefficients are divided by the smallest regression coefficient as the corresponding values, and the values are converted into a scoring system, see Table 8. The stratification and prediction performance of the scoring system in the training set, validation set and the implementation population are shown in table 12.
Implementation population 1.651 HBsAg-positive adult males in Qidong Jiangsu are subjected to measurement of relevant parameters according to the method (the detection results are shown in Table 11, the detection results are brought into a model M02, and the model M02 is adopted to screen liver cancer after risk stratification, so that 256 high-risk persons are determined by the model, and 64 high-risk persons are extremely high-risk persons.
The 651 samples were subjected to subsequent screening, including routine screening and screening based on the results of model interpretation.
The conventional HCC screening method is as follows: all personnel carry out liver cancer screening (screening positive or suspicious judgment criteria are shown in a table 10) by abdominal B ultrasonic combined serum AFP (alpha-fetoprotein), patients who screen positive (P) or screen suspicious (S) are subjected to enhanced CT detection, and the final diagnosis is subject to enhanced CT interpretation.
The total of 25 HCC patients (16 patients with extremely high risk and 9 patients with medium and high risk for model interpretation) were screened five times, which specifically were:
initial implementation time: year 2017, 10, month 3 to 12, month 13; 6 HCCs are detected and are all model-read extremely high-risk patients, wherein 2 HCCs are positive for B ultrasonic, and the tumor sizes are respectively 2.7 x 2.6cm and 5.0 x 3.0 cm;
time of second screening: 4 months 1 to 4 months 20 days in 2018; detecting 11 HCCs, wherein 8 HCCs are extremely high-risk and 3 HCCs are medium-high-risk;
time for the third screening: year 2018, 10, month 4, to 11, month 4; 1 HCC case is detected, the model interpretation is medium-high risk, B-ultrasonic positive;
fourth screening time: year 2019, 3, month 11, to 5, month 2; 6 HCCs are detected, wherein 2 HCCs are extremely high-risk cases of model interpretation, and 4 HCCs are medium-high-risk cases;
fifth screening time: 2019, 10, 15 and 11, 20; 1 HCC case is detected, the model interpretation is medium-high risk, and B-type ultrasonic positive.
TABLE 10 general screening criteria
Remarking: p represents HCC screening positive, S represents HCC screening suspicious, N represents HCC screening negative
Group 2 was performed by measuring relevant parameters according to the above method for 313 HBsAg-positive adult males in kindred of jiangsu (results are shown in table 11), and the detection results were carried into a model M02, and screening for liver cancer after risk stratification was performed using the model M02, and 176 high-risk patients were determined by the model, 51 of which are extremely high-risk patients.
Carrying out subsequent screening on the 313 samples by the same method as the implemented population 1
The three times of screening 5 HCC patients (4 cases are extremely high risk of model interpretation, and 1 case is medium-high risk), which specifically comprises the following steps:
initial implementation time: year 2018, 10, month 4, to 11, month 4; 5 cases of HCC were detected;
time of second screening: year 2019, 3, 11, 5, 2; no HCC was detected; the third screening time was: year 2019, month 9, day 1 to month 10, day 25; no HCC was detected.
The 597 samples are subsequently screened by the same screening method as the implemented population 1
7 HCC patients (5 of them are extremely high-risk patients judged by the model, and 2 of them are medium-high-risk patients) are screened out in two times, and the screening specifically comprises the following steps:
initial implementation time: year 2019, 3, 11, 5, 2; 7 cases of HCC (5 cases are extremely high-risk of model interpretation, wherein 3 cases are B-ultrasonic positive, 2 cases are medium-high-risk, and 1 case is B-ultrasonic positive) are detected;
time of second screening: year 2019, month 9, day 1 to month 10, day 25; no HCC was detected.
TABLE 11 basic characteristics of baseline levels in the implemented population, number of cases (%)
TABLE 12 layering effect corresponding to different cut-off values adopted by Male-ABCD scoring system
The total score is less than or equal to 5 and is the cut-off value of the medium-high risk group and the low-high risk group, and the total score is less than or equal to 9 and is the cut-off value of the high-high risk group and the medium-high risk group
Combining the above results, the sensitivity of the Male-ABCD model in the training set, the validation set and the implementation population is 98.60% (training set), 97.44% (validation set) and 100% (3 implementation population), respectively; the proportion (positive predictive value) of liver cancer in the extremely high risk group (accounting for 10% -25% of the population) within 24 months, 18 months, 15 months and 10 months is 25.00%, 22.59%, 7.84% and 5.21% respectively. The negative predictive values of the low-risk groups (40-60% of the population and the HCC incidence rate less than 0.2%) are 99.90% (training set), 99.73% (validation set) and 100% (3 implementation populations) respectively. Can better realize the stratification of the risk of the liver cancer of the HBsAg-positive male population.
The present invention has been described in detail above. It will be apparent to those skilled in the art that the invention can be practiced in a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation. While the invention has been described with reference to specific embodiments, it will be appreciated that the invention can be further modified. In general, this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains. The use of some of the essential features is possible within the scope of the claims attached below.
Claims (10)
1. A marker combination for predicting the risk of liver cancer in a subject to be evaluated, comprising at least one of gamma-glutamyl transpeptidase, platelets, leukocytes, albumin and indices of liver cirrhosis, and alpha-fetoprotein and abnormal prothrombin.
2. The marker combination for predicting liver cancer risk of a subject to be evaluated according to claim 1, comprising alpha-fetoprotein, abnormal prothrombin, gamma-glutamyl transpeptidase, platelets and leukocytes.
3. Use of the marker of claim 1 or 2 for the preparation of a system for predicting the risk of liver cancer in a male hepatitis b virus infected person.
4. A system for predicting liver cancer risk of a male hepatitis B virus infected person, which comprises a detection device, wherein the detection device is used for detecting the detection value of each marker in the marker combination according to any one of claims 1 to 3 in a body of a person to be evaluated.
5. The system of claim 4, further comprising an analysis module, wherein the analysis module is configured to calculate a liver cancer risk value or a liver cancer risk score according to the liver cancer risk prediction model by using the detection data obtained by the detection device, and then classify the liver cancer risk of the subject to be evaluated within 1-2 years according to the liver cancer risk value or the liver cancer risk score.
6. The system of claim 5, wherein the model for predicting liver cancer risk is represented by formula I: formula I is: liver cancer risk value (P) ═ ex/(1+ex)；
Wherein x is the sum of the intercept + the regression coefficient (beta) corresponding to the detection result of each marker in the corresponding value range.
7. The system of claim 6, wherein x in formula I is any one of:
A1) x is-7.221 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT) + beta (WBC); the corresponding liver cancer risk model is named as a liver cancer risk model M02;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; when the age is less than 60 years and is not more than 45, the beta (age) is 0.765; when the age is more than or equal to 60 and less than 65 years, the beta (age) is 1.668; when the age is more than or equal to 65 years, beta (age) is 1.62;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the AFP content is more than or equal to 7 and less than 20ng/mL, and the beta (AFP) is 1.162; the content of AFP is more than or equal to 20 and less than 80ng/mL, and the content of beta (AFP) is 1.335; the AFP content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.003; the AFP content is more than or equal to 400ng/mL, and the beta (AFP) is 3.432;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.125; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.897; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.332; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.458;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.348; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.923; the content is more than or equal to 80U/L, and the beta (GGT) is 1.381;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, and the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ] 0.423; counting<80*109L, β (PLT) ═ 1.434, where β (WBC) represents the corresponding regression coefficient of WBC counts over the respective range of values, WBC: count is not less than 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.612；
A2) x is-8.484 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT) + beta (WBC) + beta (ALB), and the corresponding liver cancer risk model is named as a liver cancer risk model M01;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.699; 60 is less than 65 years old, beta (age) is 1.665; age is more than or equal to 65 years, beta (age) is 1.595;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.217; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.471; the content of 80 is less than or equal to 400ng/mL, and beta (AFP) is 2.263; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.850;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.057; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.821; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.376; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.447;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content is more than or equal to 20 and less than 45U/L, and the beta (GGT) is 1.348; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.979; the content is more than or equal to 80U/L, and beta (GGT) is 1.463;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, and the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ] 0.426; counting<80*109/L，β(PLT)＝1.527；
Wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, and the WBC count is not less than 4 x 106L,. beta. (WBC) ═ 0; WBC count<4*106/L，β(WBC)＝0.651；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.325;
A3) x is-6.091 + beta (age) + beta (AFP) + beta (DCP) + beta (PLT), and the corresponding liver cancer risk model is named as a liver cancer risk model M04;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years, and the beta (age) is 0; age is not less than 45 and less than 60 years, beta (age) is 0.638; 60 is less than 65 years old, beta (age) is 1.594; age is more than or equal to 65 years, beta (age) is 1.424;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and beta (AFP) is 1.459; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.715; the content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.337; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.740;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 0.988; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.790; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.114; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.506;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, and the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ] 0.659; counting<80*109/L，β(PLT)＝1.887；
A4) X is-8.293 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (WBC) + beta (ALB), and the corresponding liver cancer risk model is named as a liver cancer risk model M06;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is not less than 45 and less than 60 years, beta (age) is 0.810; age 60 is less than 65 years, beta (age) is 1.798; the age is more than or equal to 65 years, and beta (age) is 1.608;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.382; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.632; the content of 80 is less than or equal to 400ng/mL, and beta (AFP) is 2.408; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.979;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.023; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.850; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.558; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.401;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.477; the content of 45 is less than or equal to 80U/L, and the beta (GGT) is 2.050; the content is more than or equal to 80U/L, and the beta (GGT) is 1.598;
wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is more than or equal to 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝1.129；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB content is less than 38g/L, the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.216;
A5) x is-8.384 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT) + beta (ALB), and the corresponding liver cancer risk model is named as a liver cancer risk model M07;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.701; 60 is less than or equal to age 65, beta (age) is 1.672; the age is more than or equal to 65 years, and beta (age) is 1.603;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.221; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.498; the content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.346; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.743;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.041; the content of 40 is less than or equal to 50mAU/mL, and beta (DCP) is 2.856; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.353; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.407;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and the beta (GGT) is 1.321; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.981; the content is more than or equal to 80U/L, and beta (GGT) is 1.433;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ═ 0.505; counting<80*109/L，β(PLT)＝1.805；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB: the content is <38g/L, beta (ALB) ═ 0; the content is more than or equal to 38g/L, and the beta (ALB) is 1.284;
A6) x is-7.115 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (WBC), and the corresponding liver cancer risk model is named as a liver cancer risk model M09;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.857; 60 is less than or equal to age 65, beta (age) is 1.781; the age is more than or equal to 65 years, and beta (age) is 1.616;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.323; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.492; the content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.165; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.579;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.079; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.917; the content is more than or equal to 50 and less than 120mAU/mL, and the beta (DCP) is 4.499; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.428;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and the beta (GGT) is 1.466; the content of 45 is less than or equal to 80U/L, and the beta (GGT) is 2.000; the content is more than or equal to 80U/L, and beta (GGT) is 1.520;
wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is more than or equal to 4 x 106/L，β(WBC)＝0；Counting<4*106/L，β(WBC)＝1.061；
A7) X is-7.162 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT), and the corresponding liver cancer risk model is named as a liver cancer risk model M10;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.762; 60 is less than 65 years old, beta (age) is 1.678; the age is more than or equal to 65 years, and beta (age) is 1.633;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and beta (AFP) is 1.161; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.376; the content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.093; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.350;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content is more than or equal to 20 and less than 40mAU/mL, and the beta (DCP) is 1.105; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.920; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.304; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.411;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.327; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.924; the content is more than or equal to 80U/L, and the beta (GGT) is 1.350;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109PLT count < 150 x 10/L9L, [ beta ] (PLT) ] 0.500; PLT counting<80*109/L，β(PLT)＝1.696；
A8) X is-8.988 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT) + beta (WBC) + beta (ALB) + beta (cirrhosis), and the corresponding liver cancer risk model is named as a liver cancer risk model CM01
Regression coefficients (β) corresponding to the detection results of each marker in the corresponding value ranges:
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.734; 60 is less than or equal to age 65, beta (age) is 1.734; the age is more than or equal to 65 years, and beta (age) is 1.640;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.090; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.302; the content is more than or equal to 80 and less than 400ng/mL, and the beta (AFP) is 2.011; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.875;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.170; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.982; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.313; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.277;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.049; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.576; the content is more than or equal to 80U/L, and beta (GGT) is 1.371;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ] 0.020; counting<80*109/L，β(PLT)＝0.766；
Wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is more than or equal to 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.333；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB content is less than 38g/L, the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.431;
wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: is, β (cirrhosis) ═ 2.108; no, β (cirrhosis) is 0;
A9) x is-7.627 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT) + beta (WBC) + beta (cirrhosis), and the corresponding liver cancer risk model is named as a liver cancer risk model CM 02;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; age is not less than 45 and less than 60 years, beta (age) is 0.806; 60 is less than or equal to age 65, beta (age) is 1.699; age is more than or equal to 65 years, beta (age) is 1.701;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and beta (AFP) is 1.063; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.179; the content of 80 is less than or equal to 400ng/mL, and the beta (AFP) is 1.732; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.614;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.242; the content of 40 is less than or equal to 50mAU/mL, and beta (DCP) is 3.086; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.305; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.277;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.057; the content of 45 is less than or equal to 80U/L, and the beta (GGT) is 1.528; the content is more than or equal to 80U/L, and the beta (GGT) is 1.258;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109L is not more than count < 150 x 109L, [ beta ] (PLT) ] 0.027; counting<80*109/L，β(PLT)＝0.647；
Wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is more than or equal to 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.301；
Wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: β (cirrhosis) ═ 2.084; no, β (cirrhosis) ═ 0;
A10) x is-4.541 + beta (age) + beta (AFP) + beta (DCP) + beta (PLT) + beta (cirrhosis), and the corresponding liver cancer risk model is named as a liver cancer risk model CM 04;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.738; 60 is less than or equal to age 65, beta (age) is 1.676; the age is more than or equal to 65 years, and beta (age) is 1.550;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content is more than or equal to 7 and less than 20ng/mL, and the beta (AFP) is 1.362; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.466; the content of 80 is less than or equal to 400ng/mL, and the beta (AFP) is 1.937; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.912;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.143; the content of 40 is less than or equal to 50mAU/mL, and beta (DCP) is 3.000; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.188; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.301;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L, [ beta ] (PLT) ═ 0.160; counting<80*109/L，β(PLT)＝0.813；
Wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: is, β (cirrhosis) ═ 2.286; no, β (cirrhosis) is 0;
A11) x is-6.681 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (WBC) + beta (ALB) + beta (liver cirrhosis), and the corresponding liver cancer risk model is named as a liver cancer risk model CM 06;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.781; 60 is less than or equal to age 65 years, beta (age) is 1.800; the age is more than or equal to 65 years, and beta (age) is 1.635;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.133; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.282; the content of 80 is less than or equal to 400ng/mL, and the beta (AFP) is 2.014; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.841;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.166; the content of 40 is less than or equal to 50mAU/mL, and beta (DCP) is 3.015; the content of 50 is less than or equal to 120mAU/mL, and the beta (DCP) is 4.362; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.219;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and the beta (GGT) is 1.065; the content of 45 is less than or equal to 80U/L, and the beta (GGT) is 1.540; the content is more than or equal to 80U/L, and the beta (GGT) is 1.378;
wherein, beta (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when the WBC count is more than or equal to 4 x 106L, [ beta ] (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.600；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB content is less than 38g/L, the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.328;
wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: β (cirrhosis) ═ 2.215; no, β (cirrhosis) is 0;
A12) x is-6.825 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT) + beta (ALB) + beta (cirrhosis), and the corresponding liver cancer risk model is named as a liver cancer risk model CM 07;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.755; 60 is less than 65 years old, beta (age) is 1.752; age is greater than or equal to 65 years, beta (age) is 1.651
Wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.093; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.325; the content of 80 is less than or equal to 400ng/mL, and the beta (AFP) is 2.034; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.844;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.157; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 2.995; the content of 50 is less than or equal to 120mAU/mL, and the beta (DCP) is 4.295; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.248;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content is more than or equal to 20 and less than 45U/L, and beta (GGT) is 1.035; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.573; the content is more than or equal to 80U/L, and the beta (GGT) is 1.343;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109Count of not less than/L < 150 x 109L,. beta. (PLT) ═ 0.056; counting<80*109/L，β(PLT)＝0.913；
Wherein, beta (ALB) represents a regression coefficient corresponding to the ALB content in a corresponding value range, and when the ALB content is less than 38g/L, the beta (ALB) is 0; the content is more than or equal to 38g/L, and beta (ALB) is 1.411;
wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: β (cirrhosis) ═ 2.136; no, β (cirrhosis) is 0;
A13) x is-5.445 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (WBC) + beta (liver cirrhosis), and the corresponding liver cancer risk model is named as liver cancer risk model CM 09;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and the value of the current age is as follows: the age is more than or equal to 35 and less than 45 years, and beta (age) is 0; age is more than or equal to 45 and less than 60 years, beta (age) is 0.836; age 60 is less than 65 years, beta (age) is 1.749; the age is more than or equal to 65 years, and beta (age) is 1.689;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.098; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.173; the content of 80 is less than or equal to 400ng/mL, and beta (AFP) is 1.751; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.607;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, when the DCP: content <20mAU/mL, β (DCP) ═ 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.232; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 3.114; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.439; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.237;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT: the content is less than 20U/L, and beta (GGT) is 0; the content of 20 is less than or equal to 45U/L, and beta (GGT) is 1.076; the content of 45 is less than or equal to 80U/L, and beta (GGT) is 1.509; the content is more than or equal to 80U/L, and the beta (GGT) is 1.275;
wherein, β (WBC) represents the regression coefficient corresponding to the WBC count in the corresponding value range, when WBC: count is not less than 4 x 106L,. beta. (WBC) ═ 0; counting<4*106/L，β(WBC)＝0.529；
Wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: is, β (cirrhosis) ═ 2.183; no, β (cirrhosis) is 0;
A14) x is-5.506 + beta (age) + beta (AFP) + beta (DCP) + beta (GGT) + beta (PLT) + beta (cirrhosis), and the corresponding liver cancer risk model is named as liver cancer risk CM 10;
wherein, beta (age) represents the regression coefficient corresponding to the age in the corresponding value range, and when the age is more than or equal to 35 and less than 45 years, the beta (age) is 0; 45 is less than or equal to age of 60 years, beta (age) is 0.822; 60 is less than or equal to age 65, beta (age) is 1.715; the age is more than or equal to 65 years, and beta (age) is 1.712;
wherein, beta (AFP) represents a regression coefficient corresponding to the AFP content in a corresponding value range, and when the AFP content is less than 7ng/mL, the beta (AFP) is 0; the content of 7 is less than or equal to 20ng/mL, and the beta (AFP) is 1.062; the content is more than or equal to 20 and less than 80ng/mL, and the beta (AFP) is 1.202; the content of 80 is less than or equal to 400ng/mL, and beta (AFP) is 1.765; the content is more than or equal to 400ng/mL, and the beta (AFP) is 3.596;
wherein, beta (DCP) represents the regression coefficient corresponding to the DCP content in the corresponding value range, and when the DCP content is less than 20mAU/mL, the beta (DCP) is 0; the content of 20 is less than or equal to 40mAU/mL, and beta (DCP) is 1.227; the content of 40 is less than or equal to 50mAU/mL, beta (DCP) is 3.095; the content of 50 is less than or equal to 120mAU/mL, and beta (DCP) is 4.286; the content is more than or equal to 120mAU/mL, and beta (DCP) is 5.246;
wherein, beta (GGT) represents a regression coefficient corresponding to the GGT content in a corresponding value range, and when the GGT content is less than 20U/L, the beta (GGT) is 0; the content is more than or equal to 20 and less than 45U/L, and the beta (GGT) is 1.046; the content is more than or equal to 45 and less than 80U/L, and the beta (GGT) is 1.527; the content is more than or equal to 80U/L, and the beta (GGT) is 1.231;
wherein, beta (PLT) represents the corresponding regression coefficient of PLT counting in the corresponding value range, when the PLT counting is more than or equal to 150 x 109/L，β(PLT)＝0；80*109L is not more than count < 150 x 109L,. beta. (PLT) ═ 0.059; counting<80*109/L，β(PLT)＝0.780；
Wherein β (liver cirrhosis) represents a regression coefficient corresponding to whether or not liver cirrhosis is diagnosed: is, β (cirrhosis) ═ 2.109; otherwise, β (cirrhosis) is 0.
8. The system of claim 6, wherein the liver cancer risk model is: the liver cancer risk score is the sum of the corresponding scores of the detection results of all markers in the corresponding value ranges; the liver cancer risk score is any one of:
B1) the liver cancer risk score is age score, AFP score, DCP score, GGT score, PLT score and WBC score, the model is named as a liver cancer risk score model M02,
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.8; the age is more than or equal to 60 and less than 65 years, and the age score is 3.9; the age is more than or equal to 65 years, and the age score is 3.8 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.7 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 3.2 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 4.7 points; the content is more than or equal to 400ng/mL, and the AFP score is 8.1 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 2.7 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 6.8 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 10.2 points; the content is more than or equal to 120mAU/mL, and the DCP score is 12.9 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 3.2 points; the content of 45 is less than 80U/L, and the GGT score is 4.5 points; the content is more than or equal to 80U/L, and the GGT score is 3.3 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 3.4 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.4 points;
B2) the liver cancer risk score is the age score, the AFP score, the DCP score, the GGT score, the PLT score, the WBC score and the ALB score, and the model is named as a liver cancer risk score model M01;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.6; the age is more than or equal to 60 and less than 65 years, and the age score is 3.9; the age is more than or equal to 65 years, and the age score is 3.7 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.9 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 3.5 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 5.3 points; the content is more than or equal to 400ng/mL, and the AFP score is 9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 2.5 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 6.6 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 10.3 points; the content is more than or equal to 120mAU/mL, and the DCP score is 12.8 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 3.2 points; the content of 45 is less than 80U/L, and the GGT score is 4.6 points; the content is more than or equal to 80U/L, and the GGT score is 3.4 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 3.6 points;
the WBC score represents the corresponding score of WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.5 points;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 3.1 points;
B3) the liver cancer risk score is age score, AFP score, DCP score and PLT score, and the model is named as a liver cancer risk score model M04;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.0; the age is more than or equal to 60 and less than 65 years, and the age score is 2.5 points; the age is more than or equal to 65 years, and the age score is 2.2 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.3 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.7 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 3.7 points; the content is more than or equal to 400ng/mL, and the AFP score is 5.9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 1.5 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 4.4 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 6.4 points; the content is more than or equal to 120mAU/mL, and the DCP score is 8.6 points;
evaluation of PLTThe score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 3.0 points;
B4) the liver cancer risk score is age score, AFP score, DCP score, GGT score, WBC score and ALB score, and the model is named as a liver cancer risk score model M06
Wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.0; the age is more than or equal to 60 and less than 65 years, and the age score is 2.2 points; the age is more than or equal to 65 years, and the age score is 2.0;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 1.7 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.0 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 3.0 points; the content is more than or equal to 400ng/mL, and the AFP score is 4.9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 1.3 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 3.5 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 5.6 points; the content is more than or equal to 120mAU/mL, and the DCP score is 6.7 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 1.8 points; the content of 45 is less than 80U/L, and the GGT score is 2.5 points; the content is more than or equal to 80U/L, and the GGT score is 2.0 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.4 points;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 1.5 points;
B5) the liver cancer risk score is age score, AFP score, DCP score, GGT score, PLT score and ALB score, and the model is named as a liver cancer risk score model M07;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.4; the age is more than or equal to 60 and less than 65 years, and the age score is 3.3 points; the age is more than or equal to 65 years, and the age score is 3.2 points;
the AFP score represents a score value corresponding to the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.4 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 3.0 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 4.6 points; the content is more than or equal to 400ng/mL, and the AFP score is 7.4 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 2.1 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 5.7 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 8.6 points; the content is more than or equal to 120mAU/mL, and the DCP score is 10.7 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 2.6 points; the content of 45 is less than 80U/L, and the GGT score is 3.9 points; the content is more than or equal to 80U/L, and the GGT score is 2.8 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 3.6 points;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, and the ALB content is less than 38g/L which is equal to 0; the content is more than or equal to 38g/L and 2.5 min;
B6) the liver cancer risk score is age score, AFP score, DCP score, GGT score and WBC score, and the model is named as a liver cancer risk score model M09;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.0; the age is more than or equal to 60 and less than 65 years, and the age score is 2.1; the age is more than or equal to 65 years, and the age score is 1.9 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 1.5 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 1.7 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 2.5 points; the content is more than or equal to 400ng/mL, and the AFP score is 4.2 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 1.3 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 3.4 points; the content is more than or equal to 50 and less than 120mAU/mL, and the DCP score is 5.3 points; the content is more than or equal to 120mAU/mL, and the DCP score is 6.3 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 1.7 points; the content of 45 is less than 80U/L, and the GGT score is 2.3 points; the content is more than or equal to 80U/L, and the GGT score is 1.8 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.2 points;
B7) the liver cancer risk score is age score, AFP score, DCP score, GGT score and PLT score, and the model is named as a liver cancer risk score model M10;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.5 points; the age is more than or equal to 60 and less than 65 years, and the age score is 3.4; the age is more than or equal to 65 years, and the age score is 3.3 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.3 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.8 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 4.2 points; the content is more than or equal to 400ng/mL, and the AFP score is 6.7 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 2.2 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 5.8 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 8.6 points; the content is more than or equal to 120mAU/mL, and the DCP score is 10.8 points;
the GGT score represents a score corresponding to the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 2.7 points; the content of 45 is less than 80U/L, and the GGT score is 3.8 points; the content is more than or equal to 80U/L, and the GGT score is 2.7 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 3.4 points;
B8) the liver cancer risk score is age score, AFP score, DCP score, GGT score, PLT score, WBC score, ALB score and cirrhosis score, and the model is named as a liver cancer risk score model CM 01;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 36.9 points; the age is more than or equal to 60 and less than 65 years, and the age score is 87.2; the age is more than or equal to 65 years, and the age score is 82.5 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content is more than or equal to 7 and less than 20ng/mL, and the AFP score is 54.8 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 65.5 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 101.1 points; the content is more than or equal to 400ng/mL, and the AFP score is 194.9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 58.9 points; the content is more than or equal to 40 and less than 50mAU/mL, and the DCP score is 150 points; the content is more than or equal to 50 and less than 120mAU/mL, and the DCP score is 217 points; the content is more than or equal to 120mAU/mL, and the DCP score is 265.4 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content of 20 is less than 45U/L, and the GGT score is 52.8 points; the content of 45 is less than 80U/L, and the GGT score is 79.3 points; the content is more than or equal to 80U/L, and the GGT score is 68.9 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 38.5 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score ═ 0 score; counting<4*106L, WBC score 16.7 points;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 72 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, the cirrhosis score is 106 points; if not, the cirrhosis score is 0;
B9) the liver cancer risk score is age score, AFP score, DCP score, GGT score, PLT score, WBC score and cirrhosis score, and the model is named as a liver cancer risk score model CM 02;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 30.1 points; the age is more than or equal to 60 and less than 65 years, and the age score is 63.4 points; the age is more than or equal to 65 years, and the age score is 63.5 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 39.7 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 44.0 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 64.6 points; the content is more than or equal to 400ng/mL, and the AFP score is 134.9 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 46.4 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 115.2 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 160.7 points; the content is more than or equal to 120mAU/mL, and the DCP score is 197 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content of 20 is less than 45U/L, and the GGT score is 39.5 points; the content of 45 is less than 80U/L, and the GGT score is 57 points; the content is more than or equal to 80U/L, and the GGT score is 47 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 24.2 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 11.2 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, the cirrhosis score is 77.8 points; if not, the cirrhosis score is 0;
B10) the liver cancer risk score is age score, AFP score, DCP score, PLT score and cirrhosis score, and the model is named as a liver cancer risk score model CM 04;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 4.6 points; the age is more than or equal to 60 and less than 65 years, and the age score is 10.4 points; the age is more than or equal to 65 years, and the age score is 9.7 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, the AFP content is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 8.5 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 9.1 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 12.1 points; the content is more than or equal to 400ng/mL, and the AFP score is 24.4 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 7.1 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 18.7 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 26.1 points; the content is more than or equal to 120mAU/mL, and the DCP score is 33.0 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 5.1 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, cirrhosis score 14.2 points; if not, the cirrhosis score is 0;
B11) the liver cancer risk score is age score, AFP score, DCP score, GGT score, WBC score, ALB score and cirrhosis score, and the model is named as a liver cancer risk score model CM 06;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.3; the age is more than or equal to 60 and less than 65 years, and the age score is 3.0; the age is more than or equal to 65 years, and the age score is 2.7 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, wherein the AFP is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 1.9 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.1 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 3.4 points; the content is more than or equal to 400ng/mL, and the AFP score is 6.4 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 1.9 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 5.0 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 7.3 points; the content is more than or equal to 120mAU/mL, and the DCP score is 8.7 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 1.8 points; the content of 45 is less than 80U/L, and the GGT score is 2.6 points; the content is more than or equal to 80U/L, and the GGT score is 2.3 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.0 point;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 2.2 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, cirrhosis score was 3.7 points; if not, the cirrhosis score is 0;
B12) the liver cancer risk score is age score, AFP score, DCP score, GGT score, PLT score, ALB score and cirrhosis score, and the model is named as a liver cancer risk score model CM 07;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 13.4 points; the age is more than or equal to 60 and less than 65 years, and the age score is 31.2 points; the age is more than or equal to 65 years, and the age score is 29.4;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, wherein the AFP is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 19.5 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 23.6 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 36.2 points; the content is more than or equal to 400ng/mL, and the AFP score is 68.4 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content is more than or equal to 20 and less than 40mAU/mL, and the DCP score is 20.6 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 53.3 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 76.5 points; the content is more than or equal to 120mAU/mL, and the DCP score is 93.4 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content of 20 is less than 45U/L, and the GGT score is 18.4 points; the content of 45 is less than 80U/L, and the GGT score is 28.0 points; the content is more than or equal to 80U/L, and the GGT score is 23.9 points;
the PLT score represents the corresponding score of the PLT count in the corresponding value range, and the PLT count is more than or equal to 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 16.3Dividing;
the ALB score represents a corresponding score of the ALB content in a corresponding value range, the ALB content is less than 38g/L, and the ALB score is 0; the content is more than or equal to 38g/L, and the ALB score is 25.1 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: is, cirrhosis score 38 points; if not, the cirrhosis score is 0;
B13) the liver cancer risk score is age score, AFP score, DCP score, GGT score, WBC score and cirrhosis score, and the model is named as a liver cancer risk score model CM 09;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 1.6; the age is more than or equal to 60 and less than 65 years, and the age score is 3.3 points; the age is more than or equal to 65 years, and the age score is 3.2 points;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, wherein the AFP is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 2.1 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 2.2 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 3.3 points; the content is more than or equal to 400ng/mL, and the AFP score is 6.8 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than 40mAU/mL, and the DCP score is 2.3 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 5.9 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 8.2 points; the content is more than or equal to 120mAU/mL, and the DCP score is 9.9 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content is more than or equal to 20 and less than 45U/L, and the GGT score is 2.0 points; the content of 45 is less than 80U/L, and the GGT score is 2.9 points; the content is more than or equal to 80U/L, and the GGT score is 2.4 points;
the WBC score represents the corresponding score of the WBC count in the corresponding value range, and the WBC count is more than or equal to 4 x 106L, WBC score 0; counting<4*106L, WBC score 1.0 point;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if yes, cirrhosis score 4.1 points; if not, the cirrhosis score is 0;
B14) the liver cancer risk score is age score, AFP score, DCP score, GGT score, PLT score and cirrhosis score, and the model is named as a liver cancer risk score model CM 10;
wherein, the age score represents the corresponding score of the age in the corresponding value range, the age is more than or equal to 35 and less than 45 years old, and the age score is 0; the age is more than or equal to 45 and less than 60 years, and the age score is 14; the age is more than or equal to 60 and less than 65 years, and the age score is 29.2 points; the age is more than or equal to 65 years, and the age score is 29.1;
the AFP score represents a corresponding score of the AFP content in a corresponding value range, wherein the AFP is less than 7ng/mL, and the AFP score is 0; the content of 7 is less than or equal to 20ng/mL, and the AFP score is 18.1 points; the content is more than or equal to 20 and less than 80ng/mL, and the AFP score is 20.4 points; the content is more than or equal to 80 and less than 400ng/mL, and the AFP score is 30.0 points; the content is more than or equal to 400ng/mL, and the AFP score is 61.2 points;
the DCP score represents a score corresponding to the DCP content in a corresponding value range, the DCP content is less than 20mAU/mL, and the DCP score is 0; the content of 20 is less than or equal to 40mAU/mL, and the DCP score is 20.9 points; the content of 40 is less than or equal to 50mAU/mL, and the DCP score is 52.7 points; the content of 50 is less than or equal to 120mAU/mL, and the DCP score is 72.9 points; the content is more than or equal to 120mAU/mL, and the DCP score is 89.3 points;
the GGT score represents a corresponding score of the GGT content in a corresponding value range, the GGT content is less than 20U/L, and the GGT score is 0; the content of 20 is less than 45U/L, and the GGT score is 17.8 points; the content of 45 is less than 80U/L, and the GGT score is 26 points; the content is more than or equal to 80U/L, and the GGT score is 20.9 points;
the PLT score represents the corresponding score of the PLT count within the corresponding value range: PLT count is not less than 150 x 109L, PLT score 0; 80*109Count of not less than/L < 150 x 109L, PLT score 1; counting<80*109L, PLT score 13.3 points;
the cirrhosis score represents the score corresponding to whether cirrhosis was diagnosed: if, cirrhosis score 35.9 points; no, cirrhosis score was 0.
9. The system of claim 7 or 8, wherein the risk level criteria for detecting liver cancer in a subject is as follows:
C1) the risk grade interpretation standard of the liver cancer risk model M02 is as follows: p is less than or equal to 0.0072, which is low risk; p is more than 0.0072 and less than or equal to 0.0319, and is medium-high risk; p >0.0319 is at very high risk;
C2) the risk grade interpretation criteria of the liver cancer risk scoring model M02 are: the score is less than or equal to 5.0, and the low risk is divided; the score is more than 5.0 and less than or equal to 9.0, the risk is medium and high; score >9.0 is extremely high risk;
C3) the risk grade interpretation standard of the liver cancer risk model M01 is as follows: p is less than or equal to 0.0068, which is low risk; p is more than 0.0068 and less than or equal to 0.0289, which is medium-high risk; p is more than 0.0289 and is extremely high risk;
C4) the risk grade interpretation standard of the liver cancer risk scoring model M01 is as follows: the score is less than or equal to 8.1, and the low risk is divided; the score is more than 8.1 and less than or equal to 11.7, the risk is medium-high; scores >11.7 are very high risk.
C5) The risk grade interpretation standard of the liver cancer risk model M04 is as follows: p is less than or equal to 0.0071, which is low risk; p is more than 0.0071 and less than or equal to 0.0283, which is medium-high risk; p is more than 0.0283 and is extremely high risk;
C6) the risk grade interpretation standard of the liver cancer risk scoring model M04 is as follows: the score is less than or equal to 1.8, and the low risk is divided; the score is more than 1.8 and less than or equal to 3.9, the risk is medium-high; scores >3.9 are very high risk.
C7) The risk grade interpretation standard of the liver cancer risk model M06 is as follows: p is less than or equal to 0.0080, which is low risk; p is more than 0.0080 and less than or equal to 0.0319, and is medium-high risk; p >0.0319 is at very high risk;
C8) the risk grade interpretation standard of the liver cancer risk scoring model M06 is as follows: the score is less than or equal to 4.3, and the low risk is divided; the medium-high risk is divided into medium-high risk when the score is more than 4.3 and less than or equal to 6.1; scores >6.1 are very high risk.
C9) The risk grade interpretation criteria of the liver cancer risk model M07 are: p is less than or equal to 0.0077, which is low risk; p is more than 0.0077 and less than or equal to 0.0299, which is medium-high risk; p is more than 0.0299, which is extremely high risk;
C10) the risk grade interpretation standard of the liver cancer risk scoring model M07 is as follows: the score is less than or equal to 7.0, and the low risk is divided; the score is more than 7.0 and less than or equal to 9.7, the risk is medium-high; scores >9.7 are very high risk.
C11) The risk grade interpretation standard of the liver cancer risk model M09 is as follows: p is less than or equal to 0.0077, which is low risk; p is more than 0.0077 and less than or equal to 0.0327, which is medium-high risk; score P >0.0327 is extremely high-risk;
C12) the risk grade interpretation standard of the liver cancer risk scoring model M09 is as follows: the score is less than or equal to 2.6, and the low risk is divided; the score is more than 2.6 and less than or equal to 4.4, the risk is medium-high; scores >4.4 were classified as extremely high risk.
C13) The risk grade interpretation standard of the liver cancer risk model M10 is as follows: p is less than or equal to 0.0078, which is low risk; p is more than 0.0078 and less than or equal to 0.0306, which is medium-high risk; p is more than 0.0306, which is extremely high risk;
C14) the risk grade interpretation standard of the liver cancer risk scoring model M10 is as follows: the score is less than or equal to 4.6, and the low risk is divided; the score is more than 4.6 and less than or equal to 7.5, the risk is medium-high; scores >7.5 are very high risk.
C15) The risk grade interpretation criteria of the liver cancer risk model CM01 are: p is less than or equal to 0.0036, which is low-risk; p is more than 0.0036 and less than or equal to 0.0250, which is medium-high risk; p is more than 0.0250, which is extremely high risk;
C16) the risk grade interpretation criteria of the liver cancer risk scoring model CM01 are: scoring less than or equal to 169 is classified as low risk; the score is more than 169 and less than or equal to 268, and the risk is high and medium; score >268 was classified as very high risk.
C17) The risk grade interpretation criteria of the liver cancer risk model CM02 are: p is less than or equal to 0.0038, which is low-risk; p is more than 0.0038 and less than or equal to 0.0259, which is medium-high risk; p is more than 0.0259 is extremely high-risk; or
C18) The risk grade interpretation criteria of the liver cancer risk scoring model CM02 are: the score is less than or equal to 77, and the low risk is divided; score of more than 77 and less than or equal to 149 is classified as medium-high risk; scores >149 were very high risk.
C19) The risk grade interpretation criteria of the liver cancer risk model CM04 are: p is less than or equal to 0.0024, which is low risk; p is more than 0.0024 and less than or equal to 0.0254, which is medium-high risk; p is more than 0.0254, which is extremely high risk;
C20) the risk grade interpretation criteria of the liver cancer risk scoring model CM04 are: the score is less than or equal to 4.9, and the low risk is divided; the score is more than 4.9 and less than or equal to 19.8, the risk is medium-high; score >19.8 is very high risk;
C21) the risk grade interpretation criteria of the liver cancer risk model CM06 are: p is less than or equal to 0.0035, which is low-risk; p is more than 0.0035 and less than or equal to 0.0286, which is medium-high risk; p is more than 0.0286 and is extremely high-risk;
C22) the risk grade interpretation criteria of the liver cancer risk scoring model CM06 are: the score is less than or equal to 5.4, and the low risk is divided; the score is more than 5.4 and less than or equal to 9.0, the risk is medium and high; score >9.0 is extremely high risk;
C23) the risk grade interpretation criteria of the liver cancer risk model CM07 are: p is less than or equal to 0.0037, which is low-risk; p is more than 0.0037 and less than or equal to 0.0261, which is medium-high risk; p is more than 0.0261, which is extremely high risk;
C24) the risk grade interpretation criteria of the liver cancer risk scoring model CM07 are: scoring less than or equal to 60 points as low risk; the score is more than 60 and less than or equal to 95, the risk is high and medium; score >95 is extremely high risk;
C25) the risk grade interpretation criteria of the liver cancer risk model CM09 are: p is less than or equal to 0.0038, which is low-risk; p is more than 0.0038 and less than or equal to 0.0281, which is medium-high risk; p >0.0281 is extremely high risk;
C26) the risk grade interpretation criteria of the liver cancer risk scoring model CM09 are: the score is less than or equal to 3.9, and the low risk is divided; the score is more than 3.9 and less than or equal to 7.7, the risk is medium-high; score >7.7 is very high risk;
C27) the risk grade interpretation criteria of the liver cancer risk model CM10 are: p is less than or equal to 0.0035, which is low-risk; p is more than 0.0035 and less than or equal to 0.0263, which is medium-high risk; p is more than 0.0263, which is extremely high risk;
C28) the risk grade interpretation criteria of the liver cancer risk scoring model CM10 are: the score is less than or equal to 33.7, and the low risk is divided; the score is more than 33.7 and less than or equal to 68.2, the risk is medium-high; scores >68.2 are very high risk.
10. The use according to claim 3 or the system according to claims 4 to 9, wherein the subject is a male HBsAg positive, preferably wherein the subject is aged 35 to 69 years.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011154456.5A CN114487426A (en) | 2020-10-26 | 2020-10-26 | Combined marker for predicting liver cancer risk of male hepatitis B virus infected person and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011154456.5A CN114487426A (en) | 2020-10-26 | 2020-10-26 | Combined marker for predicting liver cancer risk of male hepatitis B virus infected person and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114487426A true CN114487426A (en) | 2022-05-13 |
Family
ID=81471427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011154456.5A Pending CN114487426A (en) | 2020-10-26 | 2020-10-26 | Combined marker for predicting liver cancer risk of male hepatitis B virus infected person and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114487426A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116535512A (en) * | 2022-12-09 | 2023-08-04 | 中国医学科学院肿瘤医院 | Preparation and application of abnormal prothrombin monoclonal antibody for hepatocellular carcinoma patient |
-
2020
- 2020-10-26 CN CN202011154456.5A patent/CN114487426A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116535512A (en) * | 2022-12-09 | 2023-08-04 | 中国医学科学院肿瘤医院 | Preparation and application of abnormal prothrombin monoclonal antibody for hepatocellular carcinoma patient |
| CN116535512B (en) * | 2022-12-09 | 2024-03-15 | 中国医学科学院肿瘤医院 | Preparation and application of abnormal prothrombin monoclonal antibody for hepatocellular carcinoma patient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kermali et al. | The role of biomarkers in diagnosis of COVID-19–A systematic review | |
| Zhao et al. | Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are associated with chronic hepatitis B virus (HBV) infection | |
| Kim et al. | Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population | |
| Purnak et al. | Mean platelet volume is increased in chronic hepatitis C patients with advanced fibrosis | |
| Wang et al. | Novel prognostic nomograms based on inflammation-related markers for patients with hepatocellular carcinoma underwent hepatectomy | |
| Lin et al. | Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma | |
| Gan et al. | Diagnostic value of alpha-L-fucosidase for hepatocellular carcinoma: a meta-analysis | |
| CN106461664A (en) | Circulating tumor cell diagnostics for lung cancer | |
| CN111584082A (en) | Establishment and application of primary hepatocellular carcinoma microvascular invasion regression prediction model based on clinical examination multidimensional data | |
| Nagaoka et al. | The des‐γ‐carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma | |
| Nakagawa et al. | Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs | |
| Tseng et al. | Baseline Mac-2 binding protein glycosylation isomer level stratifies risks of hepatocellular carcinoma in chronic hepatitis B patients with oral antiviral therapy | |
| Kobeisy et al. | Clinical significance of elevated alpha-foetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in upper EGYPT | |
| Tian et al. | A novel risk prediction model for patients with combined hepatocellular-cholangiocarcinoma | |
| Liao et al. | Prognostic value and association of sarcopenic obesity and systemic inflammatory indexes in patients with hepatocellular carcinoma following hepatectomy and the establishment of novel predictive nomograms | |
| CN112201318A (en) | Application method of laboratory index model in risk stratification of COVID-19 patients | |
| CN114487426A (en) | Combined marker for predicting liver cancer risk of male hepatitis B virus infected person and application thereof | |
| Gumilas et al. | Potential of apolipoprotein A1 (ApoA1) for detecting liver cirrhosis and hepatocellular carcinoma | |
| Mousa et al. | Neutrophil percentage-to-albumin ratio is a new diagnostic marker for spontaneous bacterial peritonitis: a prospective multicenter study | |
| Lee et al. | Narrowed reference intervals for complete blood count in a multiethnic population | |
| Yu et al. | Development and validation of a diagnostic model for AFP-negative hepatocellular carcinoma | |
| Huang et al. | Serum N-glycan fingerprint nomogram predicts liver fibrosis: a multicenter study | |
| Kumashiro et al. | Prognostic factors for short‐term survival in alcoholic hepatitis in Japan: analysis by logistic regression | |
| Puri et al. | Study of Laboratory Parameters in COVID-19 Patients at a Tertiary Care Teaching Hospital in Uttar Pradesh | |
| Ahmed et al. | Validation of ProteinBiomarker Candidates for Diagnosis of HBV induced HCC |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |